Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 1 of 75 
CONFIDENTIAL  IND Number:  18263  
EudraCT Number:  2018 -003133 -15 Regeneron Pharmaceuticals, Inc.  
 
Clinical Study Protocol  
 
A STUDY TO EVALUATE THE EFFI CACY AND SAFETY OF 
DUPILUMAB MONOTHERAP Y IN PEDIATRIC PATIE NTS WITH 
PEANUT ALLERGY  
 
  
Compound:  REGN668 (Dupilumab)  
  
Clinical Phase:  2 
  
Protocol Number:  R668 -ALG -1702  
  
Protocol Version:  R668 -ALG -1702 Amendment 2  
Amendment 2  Date of Issue:   See appended electronic signature page  
Amendment 1 Date of Issue:   13 Dec 2019  
Original Date of Issue:  21 Aug 2018  
  
Medical /Study Director:    
 
 Regeneron Pharmaceuticals, 
Inc. 
777 Old Saw Mill River Road  
Tarrytown, NY 10591  
 
 
 
 
 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00

Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 2 of 75 
CONFIDENTIAL  TABLE OF CONTENTS  
AMENDMENT HISTORY  ................................ ................................ ................................ ............. 8 
CLINICAL STUDY PROTO COL SYNOPSIS ................................ ................................ ............. 13 
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ ................ 18 
1. INTRODUCTION  ................................ ................................ ................................ ......20 
2. STUDY OBJECTIVES  ................................ ................................ .............................. 21 
2.1. Primary O bjective  ................................ ................................ ................................ .......21 
2.2. Secondary Objectives  ................................ ................................ ................................ .21 
3. HYPOTHESIS AND RATIO NALE  ................................ ................................ .......... 21 
3.1. Hypothesis  ................................ ................................ ................................ .................. 21 
3.2. Rationale  ................................ ................................ ................................ ..................... 21 
3.2.1.  Rationale for Study Design  ................................ ................................ ......................... 21 
3.2.2.  Rationale for Dose Selection  ................................ ................................ ...................... 22 
3.2.3.  Rationale for Study Population  ................................ ................................ ................... 23 
3.3. Safety Considerations  ................................ ................................ ................................ .23 
3.3.1.  Risk Benefits for Dupilumab  ................................ ................................ ...................... 23 
3.3.2.  Risk for Peanut Protein  ................................ ................................ ............................... 24 
4. STUDY ENDPOINTS  ................................ ................................ ................................ 25 
4.1. Primary and Secondary Endpoints ................................ ................................ .............. 25 
4.1.1.  Primary Endpoint  ................................ ................................ ................................ ........ 25 
4.1.2.  Secondary Endpoints  ................................ ................................ ................................ ..25 
5. STUDY VARIABLES ................................ ................................ ................................ 25 
5.1. Demographic and Baseline Characteristics  ................................ ................................ 25 
5.2. Efficacy Variables  ................................ ................................ ................................ ......25 
5.3. Safety Variables  ................................ ................................ ................................ .......... 26 
5.4. Pharmacokinetic Variables  ................................ ................................ ......................... 26 
5.5. Immunogenicity Variables  ................................ ................................ .......................... 26 
5.6. Pharmacodynamic and Biomarker Variables  ................................ ............................. 26 
6. STUDY DESIGN  ................................ ................................ ................................ .......27 
6.1. Study Description and Duration  ................................ ................................ ................. 27 
6.1.1.  End of Study Definition  ................................ ................................ .............................. 29 
6.1.2. Study Design Safety Considerations  ................................ ................................ .......... 30 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 3 of 75 
CONFIDENTIAL  6.1.3.  Study Stopping Rules  ................................ ................................ ................................ .31 
6.1.3.1.  Individual Patient Stopping Rules (both study drug and food challenge)  .................. 31 
6.1.3.2.  Anaphylaxis  ................................ ................................ ................................ ................ 31 
6.2. Planned Interim Analysis  ................................ ................................ ............................ 31 
6.3. Study Committees  ................................ ................................ ................................ .......32 
6.3.1.  Independent Data Monitoring Committee  ................................ ................................ ..32 
7. SELECTION, WITHDRAWA L, AND REPLACEMENT O F PATIENTS  .............. 32 
7.1. Number of Patients Planned  ................................ ................................ ....................... 32 
7.2. Study Population  ................................ ................................ ................................ ......... 32 
7.2.1.  Inclu sion Criteria  ................................ ................................ ................................ ........ 32 
7.2.2.  Exclusion Criteria  ................................ ................................ ................................ .......33 
7.3. Premature Withdrawal from the Study  ................................ ................................ .......35 
7.4. Replacement of Patients  ................................ ................................ ............................. 35 
8. STUDY TREATMENTS ................................ ................................ ............................ 35 
8.1. Investigational and Reference Treatments  ................................ ................................ ..35 
8.1.1.  Peanut for Double -Blind Placebo -Controlled Food Challenge  ................................ ..35 
8.2. Rescue Treatments  ................................ ................................ ................................ ......35 
8.3. Dose Modification and Study Treatment Discontinuation Rules  ............................... 36 
8.3.1.  Dose Modification  ................................ ................................ ................................ ......36 
8.3.2.  Study Drug Discontinuation  ................................ ................................ ....................... 36 
8.3.2.1.  Reasons for Permanent Discontinuation of Dupilumab and Food Challenge  ............ 36 
8.3.2.2.  Reasons for Temporary Discontinuation of Dupilumab  ................................ ............. 36 
8.4. Management of Acute Reactions  ................................ ................................ ................ 37 
8.4.1.  Acute Injection Reactions  ................................ ................................ ........................... 37 
8.4.1.1.  Systemic Injection Reactions  ................................ ................................ ...................... 37 
8.4.1.2.  Local Injection Site Reactions  ................................ ................................ .................... 37 
8.5. Method of Treatment Assignment  ................................ ................................ .............. 37 
8.5.1.  Blinding  ................................ ................................ ................................ ...................... 38 
8.6. Treatment Logistics and Accountability  ................................ ................................ .....38 
8.6.1.  Packaging, Labeling, and Storage  ................................ ................................ .............. 38 
8.6.2.  Supply and Disposition of Treatments  ................................ ................................ .......38 
8.6.3.  Treatment Accountability  ................................ ................................ ........................... 38 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 4 of 75 
CONFIDENTIAL  8.6.4.  Treatment Compliance  ................................ ................................ ................................ 39 
8.7. Concomitant Medications and Procedures  ................................ ................................ .39 
8.7.1.  Prohibited Medications and Procedures  ................................ ................................ .....39 
8.7.2.  Permitted Medications  ................................ ................................ ................................ 40 
9. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  ................................ ......40 
9.1. Schedule of Events  ................................ ................................ ................................ .....40 
9.1.1.  Footnotes for the Schedule of Events Table  ................................ ............................... 44 
9.1.2.  Early Termination Visit  ................................ ................................ .............................. 44 
9.1.3.  Unscheduled Visits  ................................ ................................ ................................ .....45 
9.2. Study Procedures  ................................ ................................ ................................ ........ 45 
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  ................................ .....45 
9.2.2.  Efficacy Procedures  ................................ ................................ ................................ ....45 
9.2.2.1.  Double -Blind Placebo -Controlled Food Challenge  ................................ .................... 45 
9.2.2.2.  Peanut Skin Prick Test  ................................ ................................ ................................ 45 
9.2.2.3.  Food Allergy Quality of Life Questionnaire  ................................ .............................. 46 
9.2.3.  Safety Procedures  ................................ ................................ ................................ .......46 
9.2.3.1.  Vital Signs  ................................ ................................ ................................ .................. 46 
9.2.3.2.  Physical Examination  ................................ ................................ ................................ .46 
9.2.3.3.  Spirometry  ................................ ................................ ................................ .................. 46 
9.2.3.4.  Laboratory Testing  ................................ ................................ ................................ ......46 
9.2.4.  Drug Concentration and Measurements  ................................ ................................ .....48 
9.2.5.  Immunogenicity Measurements and Samples  ................................ ............................ 48 
9.2.6.  Pharmacodynamic and Exploratory Biomarker Procedures  ................................ .......48 
9.2.6.1.  Serum Thymus and Activation -Regulated Chemokine and Total IgE  ....................... 48 
9.2.6.2.  Serum Peanut -Specific A ntibody Assays (Peanut -specific IgE, IgG, IgG4)  .............. 48 
9.2.6.3.  Fractional Exhaled Nitric Oxide  ................................ ................................ ................. 49 
9.2.7.  Exploratory Research  ................................ ................................ ................................ ..49 
9.2.7. 1. Genomics Analysis  ................................ ................................ ................................ .....49 
10. SAFETY DEFINITIONS, REPORTING, AND MONIT ORING  ............................. 50 
10.1.  Obligations of Investigator  ................................ ................................ ......................... 50 
10.2.  Obligations of Sponsor  ................................ ................................ ............................... 50 
10.3.  Definitions  ................................ ................................ ................................ .................. 50 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 5 of 75 
CONFIDENTIAL  10.3.1.  Adverse Event  ................................ ................................ ................................ ............. 50 
10.3.2.  Serious Adverse Event  ................................ ................................ ................................ 50 
10.3.3. Adverse Events of Special Interest  ................................ ................................ ............. 51 
10.4.  Recording and Reporting Adverse Events  ................................ ................................ ..51 
10.4.1.  Adverse Events  ................................ ................................ ................................ ........... 51 
10.4.2.  Serious Adverse Events  ................................ ................................ .............................. 51 
10.4.3.  Other Events that Require Accelerated Reporting to Sponsor  ................................ ...52 
10.4.4.  Reporting Adverse Events Leading to Withdrawal from the Study  ........................... 52 
10.4.5.  Abnormal Laboratory, Vital Signs Results  ................................ ................................ .53 
10.4.6.  Follow -up ................................ ................................ ................................ .................... 53 
10.5.  Evaluation  of Severity and Causality  ................................ ................................ ......... 53 
10.5.1.  Evaluation of Severity  ................................ ................................ ................................ 53 
10.5.2.  Evaluation of Causality  ................................ ................................ ............................... 54 
10.6. Safety Monitoring  ................................ ................................ ................................ .......55 
10.7.  Investigator Alert Notification  ................................ ................................ .................... 55 
11. STATISTICAL PLAN ................................ ................................ ................................ 55 
11.1.  Statistical Hypothesis  ................................ ................................ ................................ ..55 
11.2. Justification of Sample Size ................................ ................................ ........................ 56 
11.3.  Analysis Sets  ................................ ................................ ................................ ............... 56 
11.3.1.  Efficacy Analysis Sets  ................................ ................................ ................................ 56 
11.3.2.  Safety Analysis Set  ................................ ................................ ................................ .....56 
11.3.3.  Pharmacokinetic Analysis Sets  ................................ ................................ ................... 56 
11.3.4.  Immunogenicity Analysis Sets  ................................ ................................ ................... 56 
11.4.  Statistical Methods  ................................ ................................ ................................ ......56 
11.4.1.  Patient Disposition  ................................ ................................ ................................ ......57 
11.4.2.  Demography and Baseline Characteristics  ................................ ................................ .57 
11.4.3.  Efficacy Analyses  ................................ ................................ ................................ .......57 
11.4.3.1 . Primary Efficacy Analysis  ................................ ................................ .......................... 57 
11.4.3.2.  Secondary Efficacy Analysis  ................................ ................................ ...................... 57 
11.4.3.3.  Multiplicity Considerations  ................................ ................................ ........................ 58 
11.4.3.4.  Timing of Analyses  ................................ ................................ ................................ .....58 
11.4.4. Safety Analysis  ................................ ................................ ................................ ........... 58 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 6 of 75 
CONFIDENTIAL  11.4.4.1.  Adverse Events  ................................ ................................ ................................ ........... 58 
11.4.4.2.  Other Safety  ................................ ................................ ................................ ................ 59 
11.4.4.3.  Treatment Exposure  ................................ ................................ ................................ ....59 
11.4.4.4.  Treatment Compliance  ................................ ................................ ................................ 60 
11.4.5.  Analysis of Drug Concentration Data  ................................ ................................ ......... 60 
11.4.6.  Analysis of Immunogenicity Data  ................................ ................................ .............. 60 
11.4.7.  Analysis of Pharmacodynamics Data  ................................ ................................ ......... 60 
11.5.  Additional Statistical Data Handling Conventions  ................................ ..................... 61 
11.6.  Statistical Considerations Surrounding the Premature Termina tion of a Study  ......... 61 
12. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ......... 62 
12.1.  Data Management and Electronic Systems  ................................ ................................ 62 
12.1.1.  Data Management  ................................ ................................ ................................ .......62 
12.1.2.  Electronic Systems  ................................ ................................ ................................ ......62 
13. STUDY MONITORING  ................................ ................................ ............................ 62 
13.1.  Monitoring of Study Sites  ................................ ................................ ........................... 62 
13.2.  Source Document Requirements  ................................ ................................ ................ 63 
13.3.  Case Report Form Requirements  ................................ ................................ ................ 63 
14. AUDITS AND INSPECTIO NS ................................ ................................ ................. 63 
15. ETHICAL AND REGULATO RY CONSIDERATIONS  ................................ .......... 64 
15.1.  Good Clinical Practice Statement  ................................ ................................ ............... 64 
15.2.  Assent and Informed Consent  ................................ ................................ ..................... 64 
15.3.  Patients Confidentiality and Data Protection  ................................ .............................. 65 
15.4.  Institutional Review Board/Ethics Committee  ................................ ........................... 65 
15.5.  Clinical Study Data Transparency  ................................ ................................ .............. 65 
16. PROTOCOL AMENDMENTS  ................................ ................................ .................. 65 
17. PREMAT URE TERMINATION OF T HE STUDY OR CLOSE -OUT OF A 
SITE  ................................ ................................ ................................ ............................ 66 
17.1.  Premature Termination of the Study  ................................ ................................ ........... 66 
17.2.  Close -out of a Site  ................................ ................................ ................................ ......66 
18. STUD Y DOCUMENTATION  ................................ ................................ ................... 66 
18.1.  Certification of Accuracy of Data  ................................ ................................ ............... 66 
18.2.  Retention of Records  ................................ ................................ ................................ ..66 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 7 of 75 
CONFIDENTIAL  19. DATA QUALITY ASSURANCE  ................................ ................................ .............. 67 
20. CONFIDENTIALITY  ................................ ................................ ................................ 68 
21. FINANCING AND INSURA NCE  ................................ ................................ ............. 68 
22. PUBLICATION POLICY  ................................ ................................ .......................... 68 
23. REFERE NCES  ................................ ................................ ................................ ........... 69 
24. INVESTIGATOR’S AGREE MENT  ................................ ................................ .......... 71 
 
LIST OF TABLES  
Table  1: Schedule of Events  ................................ ................................ ................................ .....41 
 
LIST OF FIGURES  
Figure  1: Schematic of Study Design  ................................ ................................ ......................... 27 
 
LIST OF APPENDICES  
APPENDIX  1. PEANUT DBPCFC SCHEDU LE OF DOSING PERFORM ED AT 
SCREENING AND WEEKS 24 AND 36 ................................ .......................... 72 
APPENDIX  2. ALLERGY REACTION SEV ERITY GRADING  ................................ ............ 73 
APPENDIX  3. CRITERIA FOR SUSPECT ED DIAGNOSIS AND SEV ERITY 
GRADING OF ANAPHYLAX IS ................................ ................................ ......74 
 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 8 of 75 
CONFIDENTIAL  AMENDMENT HISTORY  
Amendment 2  
The purpose of this amendment is to revise the sample size of this study in order to expose the 
minimum number of patients to serial food challenges , thereby  reduc ing the number of patients 
enrolled from 35 to 24. Other minor changes were made for clarification. A detailed list of 
changes  and their rationales can be found in the table below.  
Change  Rationale  Section Changed  
The statistical hypothesis and sample 
size calculation were re -evaluated . It is 
now assum ed that the rate of a tolerated 
cumulative dose of at least 444  mg of 
peanut protein on double -blind placebo -
controlled food challenge (DBPCFC ) at 
week 24 is 29% in dupilumab and 8% in 
placebo , based on assessment of clinical 
data from the Aimmune Therapeutics 
AR101 phase 3 study . The number of 
patients enrolled was thus reduced from 
35 to 24.  In order to expose the 
minimum number of 
patients to serial food 
challenges in this proof of 
mechanism study, the 
power analysis was 
re-evaluated. This allowed 
for enrollment of fewer 
patients to meet study 
endpoints.  Clinical S tudy Protocol Synopsis: 
Population; Statistical Plan  
Section  3.2.1  Rationale for Study 
Design  
Figure  1 Schematic of Study Design  
Section  7.1 Number of Patients Planned  
Section  8.5 Method of Treatment 
Assignment  
Section  11.1 Statistical Hypothesis  
Section  11.2 Justification of Sample 
Size 
Clarified language p ertaining to 
dupilumab prefilled syringes, packaging, 
and disposition of treatments.  For clarification.  Section  8.1 Investigational and 
Reference Tre atments  
Section  8.6.1  Packaging, Labeling, and 
Storage  
Section  8.6.2  Supply and Disposition of 
Treatments  
Text was added to specify that, while this 
is an open -label study, the study team 
will remain blinded to the order of the 
exposure for each DBPCFC at weeks 24 
and 36.  For clarification.  Section  6.1 Study Description and 
Duration  Appendix  1 Peanut DBPCFC 
Schedule of Dosing Performed at 
screening and weeks 24 and 36   
The text stating that no adjustments for 
multiplicity are planned was specified to 
be “for the secondary endpoints.”  For clarification.  Section  11.4.3.3  Multiplicity 
Considerations  
The word “tolerated” was changed to 
“passed” for the DBPCFC.  For clarification.  Clinical Study Protocol Synopsis: Study 
Design  
Section  6.1 Study Description and 
Duration  
Section  9.2.2.1  Double -Blind Placebo -
Controlled Food Challenge  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 9 of 75 
CONFIDENTIAL  Change  Rationale  Section Changed  
Specified “at least” 444 mg in the 
description of passing the DBPCFC.  For clarification.  Clinical Study Protocol Synopsis: Study 
Design; Procedures and Assessments; 
Statistical Plan  
Section  3.2.1 Rationale for Study 
Design  
Section  6.1 Study Description and 
Duration  
Section  9.1.1  Footnotes for the 
Schedule of Events Table , #10  
Section  11.1 Statistical Hypothesis  
Section  11.2 Justification of Sample 
Size 
Section  11.3.1  Efficacy Analysis Sets  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 10 of 75 
CONFIDENTIAL  Amendment 1  
The purpose of this amendment is to change the 2 -arm placebo -controlled study design to single -
arm open -label and to remove the week 12 double -blind placebo -controlled food challenge 
(DBPCFC) as a means of in creasing enrollment. Subsequent changes were made to the statistical 
analysis plan (SAP) based on this new study design. Changes were also made to align with the 
most recent dupilumab data. The following table outlines the changes made to the protocol and 
the affected sections:  
 
Change and Rationale for Change  Section Changed  
This phase 2, multicenter, proof of concept (POC) study 
was amended from a 2 -arm randomized double -blind study 
to a single -arm open -label study to increase enrollment. 
The rationale is that an open -label design in which all 
patients have access to dupilumab will decrease barriers to 
enrollment regarding concerns related to the risk of 
anaphylaxis in studying peanut protein tolerability in 
pediatric patients with a history of peanut al lergy. This is 
further justified by a low historical placebo effect in peanut 
allergy (less than 8%).  Clinical Study Protocol Synopsis: Objectives; Study 
Design; Population; Treatments; Endpoints; Statistical 
Plan 
Section  2.1 Primary Objective  
Section  2.2 Secondary Objective  
Section  3.2.1  Rationale for Study Design  
Section  3.2.2  Rationale for Dose Selection  
Section  4.1.1  Primary Endpoint  
Section  4.1.2  Secondary Endpoints  
Section  6.1 Study Description and Duration  
Figure  1 Schematic of Study Design  
Section  6.3  Study Committees  
Section  7.1  Number of Patients Planned  
Section  8.1 Investigational Reference Treatments  
Section  8.3.2.1  Reasons for Permanent Discontinuation 
of Dupilumab and Food Challenge  
Section  8.5 Method of Treatment Assignment  
Section  8.5.1  Blinding  
Table  1 Schedule of Events  
Section  10.2 Obligations of Sponsor  
Section  10.5.2  Evaluation of Causality  
Section  11.1 Statistical Hypothesis  
Section  11.2 Justification of Sample Size  
Section  11.3 Analysis Sets  
Section  11.4 Statistical Methods  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 11 of 75 
CONFIDENTIAL  Change and Rationale for Change  Section Changed  
The week 12  DBPCFC was removed , leaving only the 
DBPCFC at screening, week 24, and potentially at End 
of Study week 36. This prevents an IgE priming effect, 
and further reduces the burden on patients.  Clinical Study Protocol Synopsis: Statistical Plan  
Section  3.2.1 Rationale for Study Design  
Section  4.1.1  Primary Endpoint  
Section  4.1.2  Secondary Endpoints  
Section 6.1 Study Description and Duration  
Figure  1 Schematic of Study Design  
Table  1  Schedule of Events  
Section  9.1.1  Footnotes for the Schedule of Events, 
Footnote #1  
Section  10.4.1  Adverse Events  
Section  11.2 Justification of Sample Size  
Section  11.3 Analysis Sets  
Appendix  1 Peanut DBPCFC Schedule of Dosing 
Performed at Screening and Weeks 24 and 36  
The number of patients enrolled was changed to 35  in this  
single -arm study, instead of 48 (24 per group) in the prior 
2-arm study. This change was made because of changes 
in the study design.  
 Clinical Study Protocol Synopsis: Population; Statistical 
Plan 
Section  7.1 Number of Patients Planned  
Section  11.1 Statistical Hypothesis  
Section  11.2 Justification of Sample Size  
Section  11.3 Analysis Sets  
Section  11.4 Statistical Methods  
The dose regimen for this study was changed from 100 
mg every 2 weeks (Q2W) for patients weighing <30 kg, 
to 200 mg Q2W for patients weighing ≥20 kg and <60 
kg. This change was based on recent data from pediatric 
patients (6 to 12 years of age) with atopic dermatitis 
(AD). It was determined that 100 mg Q2W may be a 
suboptimal dose regimen for patients weighing ≥20 and 
<30 kg.  Clinical S tudy Protocol Synopsis: Study Design  
Section  3.2.2   Rationale for Dose Selection  
Section  7.2.2  Exclusion Criteria #23  
Section  8.1 Investigational Reference Treatments  
 
Changes were made to expand the pool of patients who 
may be eligible for the study by d ecreasing the level of 
serum peanut specific IgE required for inclusion from 
≥24 kUA/L to ≥10 kUA/L and/or Skin Prick Test (SPT) 
to peanut of ≥10 mm to ≥8 mm. The previous criteria 
were too restrictive compared to similar peanut allergy 
studies and the cha nge will still enroll only severely 
allergic patients who react to screening double -blind 
peanut challenge at ≤144 mg (cumulative).  Section  3.2.3  Rationale for Study Population  
Section  7.2.1  Inclusion Criteria, #4  
Section  9.2.2.2  Peanut Skin Prick Test  
 
After day 1, patients or their caregivers may administer 
drug at home with adequate training. Additionally, 
phone visits will be used (for visit # 3, 5, 7, 9, 11 and 13) 
between clinic visits. These changes were made to 
increase enrollment by decreasing th e burden of visits.  Section  6.1 Study Description and Duration  
Table  1  Schedule of Events  
Section  9.1.1  Footnotes for the Schedule of Events, 
Footnote # 1  
 
   
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 12 of 75 
CONFIDENTIAL  Change and Rationale for Change  Section Changed  
Post-treatment follow -up at week 36 is not optional if 
patients pass DBPCFC at week 24. This ch ange is due to 
the smaller sample size.  Section  6.1 Study Description and Duration  
 
DNA and research sample are no longer mandated for 
sites who have regulatory or IRB concerns. This change 
was made to comply with regulations in Canada.  Table  1 Schedule of Events  
Section  9.2.7   Exploratory Research  
Section  9.2.7.1  Genomics Analysis  
The protocol was updated for accuracy to reflect that 
approximately 10 study sites will be used in the United 
States (US) and Canada (CAN) , rather than the US and 
European Union (EU).  Clinical Study Protocol Synopsis: Site Location(s)  
Section  7.1  Number of Patients Planned  
 
Minor changes have been made to align with the most 
recent Investigator’s Brochure for dupilumab, Edition 
13. Section  1 Introduction  
Section  3 Hypothesis and Rationale  
Section  3.3 Safety Considerations  
Section  3.3.1  Risk Benefits for Dupilumab  
Other minor changes have been made throughout for 
accuracy, clarity, and to correct errors in spelling or 
grammar.  
 Section  5.5 Anti-Drug Antibody Variab les 
Section  5.6 Pharmacodynamic and Biomarker Variables  
Section  6.2 Planned Interim Analysis  
Section  7.2.1  Inclusion Criteria  
Section  7.2 Study Population  
Section  8.7.1  Prohibited Medications and Procedures  
Table  1 Schedule of Events  
Section  9.1.1  Footnotes for the Schedule of Events, 
Footnotes # 2, 3, 6, 9  
Section  9.2.2.1  Double -Blind Placebo -Controlled Food 
Challenge  
Section  9.2.2.3  Food Allergy Quality of Life 
Questionnaire  
Section  9.2.3.3  Spirometry  
Section  9.2.6   Pharmacodynamic and Explorator y 
Biomarkers Procedures  
Section  9.2.6.3  Fractional Exhaled Nitric Oxide  
Section  10.3.2  Serious Adverse Event  
Section  10.4.3  Other Events that Require Accelerated 
Reporting to Sponsor  
Section  11.3.4  Immunogenicity Analysis Sets  
Section  11.4.6  Analysis of Im munogenicity Data  
Section  15.5 Clinical Study Data Transparency  
Section  23 References  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 13 of 75 
CONFIDENTIAL  CLINICAL STUDY PROTO COL SYNOPSIS   
Title  A Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in 
Pediatric Patients with Peanut Allergy  
Site Location(s)  
 Principal Investigator  Approximately 10 sites in the United States (US) and Canada (CAN).  
Objective(s)  The primary objective of the study is to assess the tolerability of peanut 
protein in pediatric patients (6 to 17 years old) treated with dupilumab, in 
which tolerability is defined as the proportion of patients who safely pass a 
double -blind placebo -controlled food challenge (DBPCFC) at week 24.  
The secondary objectives are:  
 To determine whether dupilumab treatment improves peanut 
tolerability, define d as a change in the cumulative tolerated dose 
(log transformed) of peanut protein during a DBPCFC (up to 2044 
mg cumulative)  
 To evaluate the safety and tolerability of dupilumab treatment in 
peanut allergic patients  
 To evaluate the effects of dupilumab t reatment on the levels of 
peanut -specific IgE  
 To evaluate the treatment effect of dupilumab on the average wheal 
size after a titrated skin prick test (SPT), as measured by area under 
curve (AUC) of the average wheal size induced by peanut extract 
at diffe rent concentrations  
 To assess the incidence of treatment -emergent anti -drug antibodies 
(ADA) to dupilumab in patients over time  
Study Design  This is a phase 2, multicenter, single -arm open -label proof -of-concept 
(POC) study in pediatric patients aged 6 to  17 years inclusive who are 
allergic to peanut, to evaluate the effects of dupilumab on allergenic 
tolerance to peanut protein during a DBPCFC. The study consists of an 8 -
week screening period, a 24 -week treatment period with dupilumab, 
followed by a 12 -week safety follow -up period.  
Screening Period:  During screening visit 1 (day -57 to day -43), patients 
will undergo a medical history, physical examination, spirometry, standard 
peanut skin prick test (SPT), and laboratory testing (including peanut -
specific  IgE [sIgE]) and be evaluated for study eligibility criteria. During 
screening visit 1a (day -42 to day -15), under direct study investigator 
monitoring, patients will undergo a DBPCFC to confirm peanut allergy. 
This will consist of 5 doses (1, 3, 10, 30, and 100 mg) of peanut protein with 
a dose given every 15 to 30 minutes in increasing amounts up to a 
cumulative total of 144 mg of peanut protein. Vital signs will be assessed 
every 15 to 30 minutes. If the study team suspects a reaction may be 
developing,  they may exercise their clinical judgment to separate doses by 
up to an additional 30 minutes (1 hour maximum between doses). The 
matching placebo challenge will consist of placebo material (artificially 
peanut flavored oat protein) given also in 5 doses (1, 3, 10, 30, and 100 mg). 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 14 of 75 
CONFIDENTIAL  Both peanut and oat protein will be concealed in a food that masks the taste. 
The food challenges will be performed on different days (1 day placebo [oat] 
protein, 1 day peanut protein, with order determined at random) at least 24 
hours, but not more than 7 days, apart. All food challenges will be performed 
under physician supervision. Only patients, who experience dose -limiting 
symptoms at or before the 100 mg challenge dose of peanut protein, will be 
enrolled in the study.  
Trea tment Period:  Dupilumab will be dosed subcutaneously (SC) as 
follows based on weight at enrollment and the dose will not be changed 
regardless of weight gain or loss:  
 patients weighing ≥20 kg and <60 kg will receive dupilumab 200 mg 
Q2W following a loading  dose of 400 mg on day 1  
 patients weighing ≥60 kg will receive dupilumab 300 mg Q2W 
following a loading dose of 600 mg on day 1  
Study drug will be given in the study clinic on day 1 and then, with adequate 
training, study drug may be administered at home  Q2W. Study drug can be 
administered in the clinic at patient’s request and Principle Investigator’s 
discretion.  
Patients will have monthly clinic visits and phone calls in -between visits to 
collect adverse events (AEs), concomitant medications and compli ance to 
study drug administration.  
Double -Blind Placebo -Controlled Food Challenge : At week 24, under 
intensive monitoring, all patients will undergo a DBPCFC up to 2044 mg 
peanut protein (cumulative) or placebo to assess tolerability. The patient’s 
sensit ivity to peanut allergen is defined as the dose at which the patient 
experiences allergic reactions. All symptoms and signs will be evaluated and 
rated based on a standardized oral food challenge scoring system. Up -dosing 
during the DBPCFC will be stopped when the Principal Investigator (or 
designee) finds symptoms and/or signs that indicate a definite objective 
allergic reaction (CoFAR grading system) has occurred based on clinically 
significant changes in reported symptoms, physical findings, or vital sig ns 
that the patient is experiencing to the challenge material. Vital signs will be 
assessed every 15 to 30 minutes. The DBPCFC will consist of 8 doses 
(peanut protein or placebo), with a dose given every 15 to 30 minutes: 1, 3, 
10, 30, 100, 300, 600 mg, an d 1000 mg resulting in a total challenge of up 
to 2044 mg peanut protein (cumulative). Both peanut and oat protein will be 
concealed in a food that masks the taste. The food challenges will be 
performed on different days (1 day placebo [oat] protein, 1 day  peanut 
protein, with order determined at random) at least 24 hours but not more 
than 7 days apart and not within 24 hours of a dose of study drug. Patients 
will be considered to have passed the DBPCFC if they do not experience 
any objective Grade 1 reacti on by the CoFAR grading system.  
Follow -up Period:  All patients who complete or prematurely discontinue 
the treatment will be assessed for safety, laboratory, and clinical assessments 
12 weeks after the end of treatment. At the end of the 12 -week follow -up 
period, patients who passed a DBPCFC of at least 444 mg (cumulative) at 
week 24 will undergo a final DBPCFC (up to 2044 mg cumulative), under 
intensive monitoring, at week 36 to assess the level of peanut sensitivity 
after 12 weeks off dupilumab to determi ne whether there is evidence of 
persistent effects and sustained unresponsiveness.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 15 of 75 
CONFIDENTIAL  Study Duration  The duration of the study for a patient is approximately 36 weeks, excluding 
the screening period.  
End of Study Definition  The end of study for this study is defined as the last visit of the last patient.  
Population   
 Sample Size:  Approximately 24 patients.  
 Target Population:  Male and female pediatric patients ages 6 to 17 years with a history of peanut 
allergy confirmed by peanut SPT, sIgE and by the amount of peanut protein 
(mg) safely ingested during a peanut DBPCFC.  
Treatment(s)   
 Study Drug  
 Dose/Route/Schedule:  Dupilumab  
200 mg or 300 mg SC Q2W (weight based) following a loading dose of 400 
mg or 600 mg, respectively, on day 1.  
Endpoint(s)   
 Primary:   Proportion of patients treated with dupilumab that pass a DBPCFC with 
at least 444 mg (cumulative) peanut protein at week 24  
 Secondary:   Change in the cumulative tolerated dose (log transformed) mg of peanut 
protein during a DBPCFC from baseline to measured DBPCFC visits 
at weeks 24 and 36.  
 Proportion of patients treated with dupilumab that pass a DBPCFC with 
at least 444 mg (cumulative) peanut protein at week 36.  
 Proportion of patients treated with dupilumab that pass a DBPCFC with 
at least 1044 mg (cumulative) peanut protein at weeks 24 and 36.  
 Proportion of patients treated with dupilumab that pass a DBPCFC with 
2044 mg (cumulative) peanut protein at weeks 24 and 36.  
 Percent change from baseline in sIgE to post -baseline visits (weeks 4, 
8,12, 24 , and 36)  
 Change from baseline in titrated SPT at week 4, 12, 24, 36 as measured 
by the average wheal size AUC after peanut allergen stimulation at 
different concentrations.  
 Proportion of patients with Grade II or above allergic reactions during 
the DBPCFC  at week 24  
 Proportion of patients using epinephrine as a rescue medication during 
the DBPCFC at week 24  
Procedures and Assessments  The efficacy of dupilumab will be assessed by DBPCFC at week 24. Patients 
who passed a DBPCFC of at least 444 mg (cumulative) at week 24 will 
undergo a final DBPCFC (up to 2044 mg cumulative) at week 36.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 16 of 75 
CONFIDENTIAL  Overall safety will be assessed by monitoring/evaluation of treatment -
emergent adverse events (TEAEs), physical examinations, pulse rate, a nd 
clinical safety laboratory tests at pre -specified time points.  
Statistical Plan  Sample Size Considerations : The sample size is determined to adequately 
power the primary endpoint of the proportion of patients who pass at least a 
DBPCFC of 444 mg (cumulative) of peanut protein at week 24. Based on 
assessment of clinical data from Aimmune Therapeutics AR101 phase  3 
study, it is assumed that the rate of a tolerated cumulative dose of at least 
444 mg of peanut protein on DBPCFC at week 24 is 29% in dupilumab and 
8% in placebo . 
A sample size of 20 patients will have 80% power to detect the  29% 
tolerated rate in dupilumab group at the 2 -sided 5% significance level. 
Allowing for a dropout rate of around 15%, approximately 24 patients will 
be required. The sample size calculations were done by one -sample 
Chi-square test (normal approximation) using nQuery + nTerim 4 . 
Efficacy Analysis Set:  The full analysis set (FAS) includes all enrolled 
patients. The week 36 FAS includes patients who pass a DBPCFC of at least 
444 mg (cumulative) of peanut protein at week 24.  
Safety Analysis Set: The safety analysis set (SAF) inclu des all patients who 
received any study drug; it is based on the treatment received (as treated).  
Treatment compliance/administration and all clinical safety variables will 
be analyzed using the SAF.  
Analysis Methods  
Primary Efficacy Analysis: The FAS wil l be used for the primary efficacy 
endpoint. The primary endpoint will be analyzed using one -sample Chi -
square test. Estimate of proportion, p -value, and the 2 -sided 95% confidence 
interval will be provided.  
If a patient does not have available DBPCFC data  at week 24, the patient 
will be considered as a non -responder regardless of reasons for missing data.  
Sensitivity analyses of the primary endpoint will include an analysis of the 
subset of patients with available week 24 DBPCFC. Other sensitivity 
analyses  may be proposed in the statistical analysis plan (SAP).  
Subgroup analysis (eg, by dose group) will be performed.  
Secondary Efficacy Analysis:  All secondary endpoints will be analyzed 
descriptively at given visits.  
FAS will be used for efficacy analysis at week 24, and week 36 FAS will be 
used for efficacy analysis at week 36.  
For binary endpoints, the analysis and imputation methods will be similar to 
the primary analysis.  
A one -sample t -test will be performed to assess the change from baseline to 
week 2 4 in the cumulative tolerated dose (log transformed) of peanut protein 
during a DBPCFC. Estimate of change from baseline to week 24, p -value, 
and the 2 -sided 95% confidence interval will be provided. If the data is 
extremely skewed, nonparametric method ma y be applied. Details will be 
provided in the SAP. The missing data will be imputed by the last non -
missing DBPCFC assessment including baseline.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 17 of 75 
CONFIDENTIAL  For other continuous endpoints, the analysis and imputation methods will be 
applied similarly.  
Sensitivity ana lysis will include an analysis based on the observed cases. 
Other sensitivity analysis may be proposed in the SAP.  
Safety Analysis:  Safety analysis will be based on the SAF.  This includes 
reported TEAEs and other safety data (ie, clinical laboratory evalu ations and 
vital signs results).  A descriptive summary of safety results will be 
presented.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 18 of 75 
CONFIDENTIAL  LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
AD Atopic Dermatitis  
ADA  Anti-Drug Antibody  
AE Adverse event  
AESI  Adverse event of special interest  
ALT  Alanine aminotransferase  
ANCOVA  Analysis of covariance  
AST  Aspartate aminotransferase  
AUC  Area under curve  
BUN  Blood urea nitrogen  
CoFAR  Consortium of Food Allergy Research  
CPK  Creatine phosphokinase  
CRF  Case report form (electronic or paper)  
CRO  Contract research organization  
CRSwNP  Chronic rhinosinusitis with nasal polyposis  
DBPCFC  Double -blind, placebo -controlled food challenge  
DMC  Data monitoring committee  
DLS  Dose limiting symptom  
EASI  Eczema Area and Severity Index  
EC Ethics Committee  
EDC  Electronic data capture  
EoE Eosinophilic Esophagitis  
FAQLQ  Food allergy quality of life questionnaire  
FAS Full analysis set  
FDA  Food and Drug Administration  
FeNO  Fractional Exhaled Nitric Oxide  
FEV1  Forced Expiratory Volume in 1 Second  
GCP  Good Clinical Practice  
HBcAb  Hepatitis B core antibody  
HBsAg  Hepatitis B surface antigen  
Hep C Ab  Hepatitis C antibody  
HIV Human immunodeficiency virus  
ICF Informed consent form  
ICH International Council for Harmonisation  
IgE Immunoglobulin E  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 19 of 75 
CONFIDENTIAL  IL-4 Interleukin 4  
IDMC  Independent Data Monitoring Committee  
IL-4Rα Interleukin 4 Receptor Alpha  
IL-13 Interleukin 13  
IM Intramuscular  
IL Interleukin  
IRB Institutional Review Board  
IV Intravenous  
IWRS  Interactive web response system  
LDH  Lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Multiple imputation  
NAb  Neutralizing antibody  
OIT Oral immunotherapy  
PBMC  Peripheral blood mononuclear cells  
PCSV  Potentially clinically significant value  
PEFR/PEF  Peak expiratory flow rate  
PK Pharmacokinetic  
POC  Proof -of-concept  
PT Preferred term  
QW Weekly  
Q2W  Every 2 weeks  
RBC  Red blood cell  
Regeneron  Regeneron Pharmaceuticals, Inc.  
SAE  Serious adverse event  
SAF Safety analysis set  
SAP Statistical analysis plan  
SAS Statistical Analysis System  
SC Subcutaneous  
SCORAD  Scoring AD  
sIgE Peanut -specific IgE  
SOC  System organ class  
SPT Skin prick test  
SUSAR  Suspected unexpected serious adverse reaction  
TEAE  Treatment -emergent adverse event  
Tx Treatment  
ULN  Upper limit of normal  
WBC  White blood cell  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 20 of 75 
CONFIDENTIAL  1. INTRODUCTION  
Food allergy is a potentially life -threatening condition that affects up to 8% of young children and 
3% to 5% of the entire United States (US) population ( Gupta, 2011 ) (Sicherer, 2010 ) 
(Nwaru,  2014 ).  Unlike many other childhood allergies,  peanut allergy typically persists into 
adulthood and is associated with a higher incidence of severe anaphylaxis as compared with other 
food allergies ( Dyer, 2015 ).  The prevalence of peanut allergy by self -reports in US and European 
Union (EU) children varies from 1.2% to 2.0% ( Dunlop, 2018 ). The current remedies for food 
allergy are food avoidance and treatment with medications such a s injectable epinephrine for 
accidental exposures associated with severe allergic symptoms.  Although recent progress has been 
made in the treatment of food allergy through allergen -specific oral immunotherapy (OIT), there 
is an unmet need for a new therap y in food allergy ( Jones, 2009 ) (Anagnostou, 2011 ) 
(Anagnostou,  2014 ). The aim of OIT is to induce desensitization and increase the threshold for 
peanut ingestion, and reduce the risks of allergic reactions after accidental ingestion. However, 
many patients in OIT trials continue to have side effects that can hinder their compliance and  the 
overall efficacy of OIT. There is also a subsequent rapid loss of tolerance upon cessation of OIT 
(Vickery, 2014 ) (Wood, 2017 ).  
The im mune system in the gut actively induces an immune tolerant state to the proteins that are 
normally consumed. Food allergy occurs when the body has a break in this tolerance, which results 
in an abnormal immune reaction to food. It is known that allergic re sponse to food including peanut 
protein is an immunoglobulin E (IgE) mediated event; however, recent data suggest that 
interleukin (IL) -4 and IL -13 may also play a significant role in food allergy pathogenesis.  Cross -
linking of peanut -specific IgE (sIgE) bound to high affinity IgE receptors on mast cells and 
basophils triggers immediate degranulation. Subsequent release of a diverse array of inflammatory 
mediators results in severe allergic symptoms such as hives, wheezing, vomiting and, in severe 
cases, a naphylactic shock. Release of these mediators also initiates IL -4 and IL -13 release, which 
results in eosinophil gastrointestinal (GI) tissue infiltration and creates a cycle of chronic Type 2 
allergic inflammation ( Wong, 2016 ). 
Dupilumab, a fully human VelocImmune®-derived monoclonal antibody directed against 
interleukin -4 receptor alpha (IL -4Rα), blocks the activity of IL -4 and IL -13 and is approved as a 
treatment for atopic dermatitis (AD).  As of October 2019, dupilumab has been approved for the 
adult atopic dermatitis (AD) indication in over 40 countries worldwide. Additionally, dupilumab 
has been approved for severe asthma with type 2 inflammation in both adult and adolescent 
patients, and recent ly in adult patients with  chronic rhinosinusitis with nasal polyposis  (CRSwNP), 
and adolescents with AD. Dupilumab is also under development for a range of type 2 inflammatory 
diseases such as food allergies and eosinophilic esophagitis (EOE) amongst other s. 
This phase 2 proof -of-concept (POC) study will explore whether dupilumab has 
immunomodulatory effects on Type 2 immune responses, which may result in improved safety 
and tolerance to peanut exposure as determined by the ability to tolerate a higher cumu lative peanut 
protein dose level during a double -blind, placebo -controlled food challenge (DBPCFC) after 
24 weeks of monotherapy treatment. In addition, the study will evaluate whether dupilumab 
influences known biomarkers important in the allergic respons e to peanuts such as a reduction in 
allergen -specific IgE and/or increase in allergen -specific IgG4.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 21 of 75 
CONFIDENTIAL  Additional background information on the study drug and development program can be found in 
the Investigator’s Brochure.  
2. STUDY OBJECTIVES   
2.1. Primary Objectiv e 
The primary objective of the study is to assess the tolerability of peanut protein in pediatric patients 
(6 to 17 years old) treated with dupilumab monotherapy, in which tolerability is defined as the 
proportion of patients who safely pass a double -blind  placebo -controlled food challenge 
(DBPCFC) at week 24.  
2.2. Secondary Objectives  
The secondary objectives of the study include:  
 To determine whether dupilumab treatment improves peanut tolerability, defined as a 
change in the cumulative tolerated dose (log tra nsformed) of peanut protein during a 
DBPCFC (up to 2044 mg cumulative)  
 To evaluate the safety and tolerability of dupilumab treatment in peanut allergic 
patients  
 To evaluate the effects of dupilumab treatment on the levels of peanut -specific IgE  
 To evaluate the treatment effect of dupilumab on the average wheal size after a titrated 
skin prick test (SPT), as measured by area under the curve (AUC) of the average wheal 
size induced by peanut extract at different concentrations.  
 To assess the incidence of treatment -emergent anti -drug antibodies (ADA) to 
dupilumab in patients over time  
3. HYPOTHESIS AND RATIO NALE   
3.1. Hypothesis  
In pediatric patients with peanut allergy, treatment with dupilumab will result in inhibition of the 
Type 2 immune response and increase  the threshold amount of peanut protein that triggers a 
clinically measurable allergic reaction.  
3.2. Rationale  
3.2.1.  Rationale for Study Design  
Dupilumab will be tested in a single -arm open -label POC study of 24 weeks subcutaneous (SC) 
dupilumab (every 2 weeks [Q2W]) treatment period and 12 -week safety follow -up period in 
approximately 24 pediatric patients with confirmed peanut allergy.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 22 of 75 
CONFIDENTIAL  Assessing the proportion of patients who tolerate at least 444 mg (cumulative) peanut protein 
during a DBPCFC before and a fter 24 weeks of dupilumab therapy will provide clinically relevant 
information  about the potential increase in the peanut allergic threshold for protection from 
accidental exposure to approximately 2 peanut kernels.  
The time course of dupilumab efficacy i n peanut allergy is not yet established.  It is thought the 
onset of action could  coincide with reduction of sIgE and suppression of Type 2 effector cells. 
Dupilumab suppresses Type 2 inflammation, as measured by circulating markers such as 
Chemokine (C -C motif) Ligand 17 (also known as thymus and activation regulated chemokine 
[TARC]), within 4 to 12 weeks of treatment in all indications tested to date. Type 2 T -helper and 
effectors also play a major role in the onset of peanut allergy. In past AD studies,  CD3+ T -cell 
infiltration in the skin was shown to significantly decrease from weeks 4 to 16.  This suggests 
dupilumab may suppress the activity of pathogenic Th2 cells effectively in 16 weeks. Thus, a 
24 week study is expected to be sufficient to evaluate  the onset of effects of dupilumab on peanut 
protein tolerability. Evaluation of effect at week 36 when the dupilumab concentration should be 
below the lower limit of quantitation will assess the persistence of immune modulation following 
12 weeks off trea tment.  
3.2.2.  Rationale for Dose Selection  
The approved dosing  regimen in the US and EU for the treatment of AD in adults is 300 mg Q2W. 
Doses of 300 mg Q2W and 300 mg weekly (QW) were shown to have an acceptable safety profile 
in adult AD patients in 2 phase 3 s tudies. In addition, 300 mg Q2W had an acceptable safety profile 
in a phase 2b study in adults with persistent asthma ( Wenzel, 2016 ) and in a phase 3 study in 
patients ≥12 years of age with uncontro lled moderate -to-severe asthma ( Busse, 2018 ).  The dose 
justification for pediatric patients aged 6 to <12 years old is based on the efficacy and safety 
observed in the global phase 3 monotherapy st udies in adult AD patients (R668 -AD-1334 and 
R668 -AD-1416) and adolescent patients (R688 -AD-1526), together with the observed efficacy, 
safety and PK modeling of data gathered from a study of AD patients aged 6 to 18 years (R668 -
AD-1412). In pediatric pati ents receiving 4 mg/kg QW for 4 doses, exposures similar to those in 
adults receiving 300 mg Q2W dupilumab were achieved in the first study (R668 -AD-1412), where 
significant improvement in measures of AD were noted, with an acceptable safety profile. 
Simil arly, in the pivotal, phase 3 study in adolescent patients (R668 -AD-1526), dupilumab 
monotherapy resulted in significant improvements in measures of AD and had an acceptable safety 
profile. Considering these data, 300 mg Q2W dupilumab is a suitable dose fo r adolescent and adult 
patients >60 kg with confirmed peanut allergy. The weight -based doses chosen for treatments in 
this study represent the doses of dupilumab, which are modeled to result in exposure to dupilumab 
that is associated with efficacy in AD i n adults and adolescents. The dupilumab SC dose will be 
300 mg Q2W in children ≥60 kg following a loading dose of 600 mg on day 1. Children who 
weigh 20 kg or more but less than 60 kg, will receive 200 mg Q2W following a loading dose of 
400 mg on day 1. Th ese dose regimens are also being tested in the pediatric AD studies.  
Bi-weekly dupilumab dosing should allow for adequate drug exposure without adversely 
impacting safety. Study drug may be administered in the clinic or at home by the study team, 
patient’ s caregiver, or patient. For patients under 12 years old, caregiver injections will be required.  
The administration  of the loading dose of dupilumab is the approach that was used for other 
symptomatic conditions where early onset is appropriate, and the sa me approach is followed here.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 23 of 75 
CONFIDENTIAL  3.2.3.  Rationale for Study Population  
Dupilumab has been well tolerated with a favorable safety profile in pediatric patients in studies 
to date (see below). The lower cutoff of 6 years of age was selected to include only patients wi th 
sufficient blood volumes to perform the mechanistic and safety studies blood measurements every 
month or per schedule of events  (±1 clinic visit). A weight cut off of 20 kg to be compliant with 
Institutional Review Board (IRB) guidelines (ie, for childr en: 5 mL/kg at any single draw, no more 
than 9.5 mL/kg over an 8 -week period; adults: the smaller of 10.5 mL/kg or 550 ml total at any 
single draw). The upper age limit of 17 years was selected because the majority of patients with 
peanut allergy are in th e pediatric population. Patients will be enrolled with proven peanut allergy 
with serum IgE to peanut of ≥10 kUA/L and/or an SPT to peanut ≥8 mm compared to a negative 
control. In addition, a clinical reaction during a DBPCFC ≤100 mg peanut protein (144 mg  
cumulative) and no clinical reaction during placebo (oat) will ensure the enrollment of only highly 
reactive patients.  
3.3. Safety Considerations  
Unlike many other childhood allergies, peanut allergy typically persists into adulthood and is 
associated with a h igher incidence of severe anaphylaxis as compared with other food allergies 
(Dyer, 2015 ). Although recent progress has been made in the treatment of food allergy through 
allergen -specific OIT, side effects, primarily GI related, often limit its full efficacy in many 
patients and there  is an unmet need for a new therapy in food allergy. It is known that allergic 
response to food is an IgE mediated event; however, recent data suggest that non -IgE related, IL -
4/13 mediated Type 2 inflammation may also play a significant role in food aller gy pathogenesis 
(Yu, 2016 ). Consequently, dupilumab treatment would be expected to provide benefit by blocking 
the activity of IL -4 and IL -13 and decreasing Type 2 immune responses and production of  peanut -
specific IgE. As of 28 March 2019, dupilumab has been well tolerated in all completed studies, 
including studies in AD, asthma, nasal polyps, EoE, grass allergy and peanut allergy.  
3.3.1.  Risk Benefits for Dupilumab  
At the time of writing this protocol, d upilumab 300 mg Q2W had been approved in the US, the 
EU, and several other countries including Japan for the treatment of adults with moderate -to-severe 
AD. Marketing applications are under review in additional countries. Dupilumab received 
approval from U S Food and Drug Administration (FDA) on 11 March 2019 and from European 
Union European Commission on 1 August 2019 for use in adolescent patients (≥12 years) with 
moderate to severe atopic dermatitis. Review of this indication is ongoing in a number of oth er 
countries worldwide. Fourteen clinical studies (phases 1 through 3) of repeated -doses of 
dupilumab in AD patients have been completed. Dupilumab has demonstrated robust and 
consistent efficacy in completed clinical trials, across a variety of clinical o utcomes, reflecting 
clinically meaningful and statistically significant improvement in AD signs, symptoms and quality 
of life with sustained efficacy demonstrated to 52 weeks. Dupilumab was well tolerated in these 
studies with a favorable safety profile.  
Dupilumab’s efficacy  in adult patients with moderate -to-severe uncontrolled asthma has also been 
demonstrated at doses of 200 mg or 300 mg Q2W for 24 weeks (DRI12544) and 52 weeks 
(EFC13579). Dupilumab received approval from US FDA on 19 October 2018 for us e in adults 
and adolescents (≥12 years) with moderate -to-severe asthma with an eosinophilic phenotype or 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 24 of 75 
CONFIDENTIAL  corticosteroid dependent asthma. In the European Union, dupilumab received a marketing 
authorization approval from the European Commission on 6 May 201 9 for use in adults and 
adolescents (≥12 years) with severe asthma with type 2 inflammation. In Japan, dupilumab 
received approval from Pharmaceuticals and Medical Devices Agency on 26 March 2019 for use 
in adults and adolescents (≥12 years) with severe or  refractory bronchial asthma. Asthma is a 
common comorbidity of allergy and asthma exacerbations are an important safety concern for food 
challenges. In these studies, treatment with dupilumab at all doses tested was generally well 
tolerated with a favorab le safety profile.  
The first clinical study of dupilumab in pediatric patients aged 6 years to <18 years old with AD 
(R668 -AD-1412) has been completed. Data generated from this study showed that dupilumab 
administered as single  and repeated weekly doses (u p to 4 weeks) was generally well tolerated and 
had an acceptable safety profile similar to that for adults in both pediatric age groups included in 
this study (6 to 11 years and 12 to <18 years). There were no new safety signals detected with 
dupilumab in this pediatric population. Most of the AEs reported were mild in intensity, transient 
in nature and not related to the study drug. Both dose regimens of dupilumab evaluated (2 mg/kg 
and 4 mg/kg) showed significant clinical benefit in both pediatric age gro ups. In the pivotal, phase 
3 study in adolescent patients (R668 -AD-1526) the overall rate of AEs was comparable between 
the dupilumab groups and placebo (72% for dupilumab Q2W, 64% for dupilumab Q4W and 69% 
for placebo). There were no serious adverse event s (SAEs) or events leading to treatment 
discontinuation in either dupilumab treatment group. Adverse events that were observed at a higher 
rate with dupilumab included Injection Site Reactions (8.5% for dupilumab Q2W, 6% for 
dupilumab Q4W, compared with 3. 5% for placebo) and Conjunctivitis (10% for dupilumab Q2W, 
11% for dupilumab Q4W, compared with 5% for placebo). Skin Infections were numerically lower 
in the dupilumab groups (11% for dupilumab Q2W, 13% for dupilumab Q4W, compared with 
20% for placebo). A s of 28 March 2019, the estimated total number of subjects exposed to 
dupilumab in clinical studies was 7781 (218 in healthy volunteer studies, 3931 in AD studies, 3073 
in asthma studies, 470 in CRSwNP studies, 26 EoE studies, and 63 in grass allergy and p eanut 
allergy studies). In all completed studies, dupilumab has been well tolerated and has demonstrated 
significant and prolonged efficacy in all Type 2 immune indications investigated to date.  
Additional information can be found in the Investigator’s Bro chure.  
3.3.2.  Risk for Peanut Protein  
Oral food challenges may induce a severe life -threatening allergic reaction; however, the risk can 
be greatly mitigated by conducting  the challenges in a highly monitored setting and by initiating 
the challenge with a very sm all amount of the food, gradually increasing the dose, and stopping 
the challenge at the first sign of a reaction. If patients develop an allergic reaction during the 
challenges, they may need oral, intramuscular (IM), or intravenous (IV) medications. Addi tionally, 
IV catheters may be placed, at physician discretion for any visit, based on factors such as previous 
reactions, recent clinical history, and clinical status observed at the visit. Trained personnel, 
including a study physician, as well as medicat ions and equipment, will be immediately available 
to treat any reaction. Based on similarly designed previous clinical studies, the anticipated rate of 
life-threatening anaphylactic reactions is <0.1%. There may be a risk that during the study patients 
may decrease their vigilance against accidental food allergen ingestion because they believe they 
are protected from it. Therefore, patients/caregivers will be warned that they should continue to 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 25 of 75 
CONFIDENTIAL  practice their usual vigilance against accidental ingestion of food allergens or food allergen -
containing foods and reminded to carry their epinephrine autoinjector at all times.  
4. STUDY ENDPOINTS  
4.1. Primary and Secondary Endpoints  
4.1.1.  Primary Endpoint  
 Proportion of patients treated with dupilumab that pass a DBPCFC with at le ast 
444 mg (cumulative) peanut protein at week 24  
4.1.2.  Secondary Endpoints  
 Change in the cumulative tolerated dose (log transformed) mg of peanut protein 
during a DBPCFC from baseline to measured DBPCFC visits at weeks 24 and 36.  
 Proportion of patients treated with dupilumab that pass a DBPCFC with at least 
444 mg (cumulative) peanut protein at week 36.  
 Proportion of patients treated with dupilumab that pass a DBPCFC with at least 
1044  mg (cumulative) peanut protein at weeks 24 and 36.  
 Proportion of patients tre ated with dupilumab that pass a DBPCFC with 2044 mg 
(cumulative) peanut protein at weeks 24 and 36.  
 Percent change from baseline in sIgE to post -baseline visits (weeks 4, 8,12, 24, and 
36) 
 Change from baseline in titrated SPT at week 4, 12, 24, 36 as measu red by the 
average wheal size AUC after peanut allergen stimulation at different concentrations.  
 Proportion of patients with Grade II or above allergic reactions during the DBPCFC 
at week 24  
 Proportion of patients using epinephrine as a rescue medication d uring the DBPCFC 
at week 24  
5. STUDY VARIABLES  
5.1. Demographic and Baseline Characteristics  
Baseline characteristics  will include standard demography (eg, age, race, weight, height, co -
morbid atopic conditions, years with food allergy disease, sex, etc), disease characteristics 
including medical history, and medication history for each patient.  
5.2. Efficacy Variables  
Efficacy variables will include the DBPCFC and the peanut SPT.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 26 of 75 
CONFIDENTIAL  5.3. Safety Variables  
Safety variables will include vital signs, spirometry (Forced Expiratory Volume in 1 Second 
[FEV1] and/or peak expiratory flow rate [PEFR]), hematology and chemistry, urinalysis, and AEs.  
5.4. Pharmacokinetic Variables  
Concentration of functional dupilumab in serum at each time point, obtained prior to dosing, will 
considered to be trough values (C trough time point ). 
5.5. Immunogenicity Variables  
The immunogenicity variables are ADA status, titer, neutralizing antibody (NAb) status, and time -
point/visit.  
5.6. Pharmacodynamic and Biomarker Variables  
Serum TARC and Total IgE . Serum TARC and tota l IgE are markers of Type 2 activity. 
Dupilumab significantly  suppressed both TARC and total IgE in studies of adult AD, nasal 
polyposis, and asthma patients.  
Peanut -specific IgE, IgG, IgG4 . The induction of peanut -specific IgG4 and IgG during OIT has 
been  reported in multiple studies, and is thought to have a protective effect against IgE -mediated 
allergic symptoms. The gradual increase in serum allergen -specific IgG4, and decrease in allergen -
specific IgEs are associated with clinical desensitization to p eanut ( Glaumann, 2015 ). In a 5 -year 
peanut OIT study of 39 peanut -allergic children, increases in total peanut -specific IgG levels were 
reported during the 12 -month up -dosing period ( Vickery, 2014 ). In an open -label study of 29 
peanut -allergic children, peanut -specific IgG4 increased steadily during the first year of treatment, 
reaching 3.5 -fold increase over baseline after 3 months of OIT and roughly 10 -fold increase at the 
end of first year ( Jones, 2009 ). In the same study, peanut -specific IgE increased by ~3 fold after 
3 months of OIT and gradually returned to baseline at one year. In a study investigating the 
biomarker profile of dupilumab in patients with AD (R668 -AD-1307 as well as other dupilumab 
studies), dupilumab suppressed both total and allergen -specific IgEs. In general, dupilumab 
suppresses total serum IgE by ~ 50% with 12 to 16 weeks of treatment.  
Titrated Skin Prick Test. The titrated SPT wi ll assess the atopic response to peanut extract. A 
statistically significant reduction in wheal size has been associated with clinical desensitization for 
peanut allergy in a randomized controlled study of peanut OIT for 12 months ( Varshney,  2011 ). 
Fractional Exhaled Nitric Oxide . Fractional exhaled nitric oxide (FeNO) is a non -invasive 
marker that has been shown to correlate with allergic airway inflammation and IgE sensitization. 
The measurement  of FeNO has shown predictive value on the outcome of peanut oral food 
challenge ( Preece, 2014 ) In a 12 -month -study enrolling 56 patients with peanut allergy, FeNO 
measurement demonstrated superior reproducibility (ICC=0.73) in compa rison to peanut skin 
prick test (ICC=0.51), Ara h2 skin prick test (ICC=0.44) ( Percival, 2016 ). In past studies, 
dupilumab significantly lowered FeNO concentrations in asthma patients. Asthma is a common 
comorbid condition in peanu t allergic patients (>50%). It is plausible that peanut exposure during 
DBPCFC in these patients may trigger an increase in FeNO and asthmatic symptoms. Thus, 
dupilumab treatment may suppress FeNO induction after an oral food challenge. Although no 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 27 of 75 
CONFIDENTIAL  manufac turer has validated the FeNO device for children under 7 years old due to inadequate 
exhalation force, there are no contraindications with the use of FeNO for 6 -year-old children.  
Additionally, specific guidance and reference ranges are available for coll ection in children as 
young as 6 years of age ( Brody, 2013 ) (Menou, 2017 ). As FeNO is an exploratory biomarker, it 
will be collected for children 6 years old unless the investigator declines to collect. FeNO will be 
collected prior to spirometry.  
Other Exploratory Research  
Blood may be obtained for additional exploratory tests research to understand better allergy and 
peanut allergy. Blood samples collected for exploratory research will be kept for up to 15 years 
for studying the allergen response ex vivo.  
The results of exploratory  analyses will not be presented in the CSR.  
6. Study Design  
6.1. Study Description and Duration  
This is a phase 2, multicenter , single -arm open -label POC study in pediatric patients aged 6 to 
17 years inclusive who are allergic to peanut, to evaluate the effects of dupilumab on tolerability 
of peanut protein during a DBPCFC. The study consists of an 8 -week screening pe riod, 24 -week 
open -label treatment period with dupilumab, followed by a 12 -week safety follow -up period 
(Figure  1). 
Figure  1: Schematic of Study Design  
 
Screening  
After  obtaining informed consent/assent, patients will be assessed for eligibility during a 2 -part 
screening period. During screening visit 1 (day -57 to day -43), patients will undergo a medical 
history, physical examination, spirometry, peanut SPT, and labora tory testing (including sIgE) and 
will be evaluated for the study eligibility criteria.  
During screening visit 1a (day -42 to day -15), under direct study investigator monitoring, patients 
will undergo a DBPCFC to confirm current peanut allergy. This will consist of 5 doses of peanut 
protein with a dose given every 15 to 30 minutes in increasing amounts up to a cumulative total of 
144 mg of peanut protein ( Appendix  1). Vital signs will be assessed every 15 to 30 minutes. If the 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 28 of 75 
CONFIDENTIAL  study team suspects a reaction may be developing, they may exercise their clinical judgment to 
separate doses by up to an additional 30 minutes (1 hour maximum between doses). T he matching 
placebo challenge will consist of placebo material (oat protein) given also in 5 doses. Both peanut 
and oat protein will be concealed in a food that masks the taste. The food challenges will be 
performed on different days (1 day placebo [oat] p rotein, 1 day peanut protein, with order 
determined at random) at least 24 hours, but not more than 7 days, apart. The doses will be 1, 3, 
10, 30, and 100 mg of peanut protein (or placebo). Both food challenge days (placebo and peanut) 
must be done to eval uate eligibility.  
Before each challenge, the patient will have a physical assessment by a trained physician’s 
assistant, registered nurse, nurse practitioner, and/or physician of the study team who is blinded to 
the testing material. The supervising invest igator will also be blinded to testing material.  
Reactions will be scored using the Consortium of Food Allergy Research (CoFAR) grading system 
(see Appendix  2). The DBPCFC will be stopped when the blinded assessor finds symptoms and/or 
signs that indicate a definite objective allergic reaction (CoFAR grading system [see Appendix  2]) 
has occurred based on clinically significant changes in reported symptoms, physical findings, or 
vital signs  that the patient is experiencing to the challenge material. The patient will be observed 
for a minimum of 2 hours after the final administered dose and discharged only when deemed 
clinically stable by a study physician. All food challenges will be performed under physician 
supervision. If the patient does not experience dose -limiting symptoms at or before the 10 0 mg 
challenge dose (≤144 mg cumulative) of peanut protein or if he/she experiences symptoms at any 
dose of placebo, he/she will not be enrolled in the study. Investigator/site personnel will be 
unblinded only to the results of the screening food challenge  upon completion of the second part 
of the challenge to assess eligibility. A 2 -week washout period is needed after the screening 
DBPCFC where peanut was given. All other on -study food challenges in the study will remain 
blinded  to the clinic study team . 
Treatment Period  
Patients with a history of confirmed peanut allergy signs and symptoms at screening who 
continue to meet eligibility criteria at baseline will be enrolled.  
Dupilumab  will be dosed SC on day 1 at least 14 days after the screening DBPCFC (thi s interval 
was selected to ensure that accurate biomarker values at baseline are captured) and the dose will 
not be changes regardless of weight gain or loss:  
 patients weighing ≥20 kg and <60 kg will receive dupilumab 200 mg Q2W following 
a loading dose of  400 mg on day 1  
 patients weighing ≥60 kg will receive dupilumab 300 mg Q2W following a loading 
dose of 600 mg on day 1  
Study drug may be administered in the clinic on day 1 by the study team, patient’s caregiver, or 
patient. Patient and/or caregiver wil l be trained on how to store, handle, prepare, and administer 
study drug at home Q2W. The last dose of study drug will be at week 22. For patients under 
12 years of age, adult caregiver will need to administer the study drug injections.  
Patients will have monthly clinic visits and phone calls in -between visits to collect AEs, 
concomitant medications and compliance to study drug administration.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 29 of 75 
CONFIDENTIAL  Double -Blind Placebo -Controlled Food Challenge  
At week 24, under intensive monitoring, all patients will undergo a DBPCFC up to 2044 mg peanut 
protein (cumulative) or placebo (see Appendix  1) to a ssess tolerability. The patient’s sensitivity to 
peanut allergen is defined as the dose at which the patient experiences allergic reactions. All 
symptoms and signs will be evaluated and rated based on a standardized oral food challenge 
scoring system (see Appendix  2). Up -dosing during the DBPCFC will be stopped when the blinded 
assessor finds symptoms and/or signs that indicate a definite objective al lergic reaction (CoFAR 
grading system [see Appendix  2]) has occurred based on clinically significant changes in reported 
symptoms, physical findings,  or vital signs that the patient is experiencing to the challenge 
material. Vital signs will be assessed every 15 to 30 minutes. The DBPCFC will consist of 8 doses 
(peanut protein or placebo), with a dose given every 15 to 30 minutes: 1, 3, 10, 30, 100, 30 0, 600 
mg, and 1000 mg resulting in a total challenge of up to 2044 mg peanut protein (cumulative). Both 
peanut and oat protein will be concealed in a food that masks the taste. The food challenges will 
be performed on different days (1 day placebo [oat] p rotein, 1 day peanut protein, with order 
determined at random) at least 24 hours but not more than 7 days apart and not within 24 hours of 
a dose of study drug. Patients will be considered to have passed the DBPCFC if they do not 
experience any objective G rade 1 reaction by the CoFAR grading system (see Appendix  2). If the 
patient experiences reactions, he/she will be treated with the necessary rescue medications. He/she 
will be observed for a minimum of 2 hours after the final administered dose and discharged only 
when deemed clinically stable by a study physician. Symptom severity will be adjudicated by an 
independent, blinded assessor who is not invo lved in patient study visit conduct ( Bock, 1988 ; 
Sampson, 2006 ). 
Study design safety considerations for DBPCFC are described in Section  3.3.2 . 
Post-Treatment Follow -up Period (12 weeks)  
All patients will have  a 12-week follow -up period after the end of treatment and will undergo 
safety, laboratory, and clinical assessments.  
The duration of the 12 -week follow -up period is based on the time expected for drug levels (to be 
below the lower limit of quantification ) after the last dose of dupilumab. At the end of the 12 -week 
follow -up period, only patients who passed a  DBPCFC  of at least 444 mg (cumulative) at week 24 
will undergo a final DBPCFC (up to 2044 mg cumulative), under intensive monitoring, at week 
36 to a ssess the level of peanut sensitivity after 12 weeks off dupilumab to determine whether there 
is evidence of persistent effects and sustained unresponsiveness.  
6.1.1.  End of Study Definition  
The end of study is defined as the last visit of the last patient.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 30 of 75 
CONFIDENTIAL  6.1.2.  Study  Design Safety Considerations  
The design considers important safety issues:  
 All DBPCFC visits will be supervised in -clinic setting where trained study physicians 
are available  
 Standing orders from a medical doctor are provided for all clinical study person nel to 
initiate treatment of reactions immediately (ie, prior to medical doctor notification), 
including IM administration of epinephrine, based on their own clinical judgment  
 A crash cart with pediatric equipment will be available in close proximity (with in 
50 feet) of all patient clinic rooms  
 A code team is available  
 Dosing allergic symptoms and AEs will be captured throughout the study  
 Patients will be prescribed an epinephrine auto -injector (if not prescribed by a treating 
clinician previous to study en try) and all patients/Caregivers will be trained in its use. 
Patients will be advised to carry the autoinjector with them at all times.  
 Patients /caregivers will be cautioned against patients consuming any peanuts or 
peanut -containing foods other than the peanut allergen challenge while on study  
 The dupilumab clinical development program in food allergy independent data 
monitoring committee (IDMC) will provide oversight of patient safety. The IDMC 
will provide Regeneron and Sanofi with appropriate recommend ations on the conduct 
of the food allergy clinical studies to ensure the protection and safety of the patients 
enrolled in these studies.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 31 of 75 
CONFIDENTIAL  6.1.3.  Study Stopping Rules  
6.1.3.1.  Individual Patient Stopping Rules (both study drug and food challenge)  
1. Missing ≥2 consecutive dos es of study drug  
2. Anaphylaxis resulting in severe hypotension ( Appendix  3), neurological compromise or 
mechanical ventilation secondary to any food c hallenge ( Simons, 2014 ). 
3. Patient develops biopsy -documented eosinophilic esophagitis (EoE) or other eosinophilic 
gastrointestinal disease.  
4. Any patient deemed to have severe allergic reactions and wh o receives aggressive 
therapy (eg, mechanical ventilation, 3 or more repeated doses of epinephrine for a life -
threatening reaction) at any time will be discontinued from further therapy.  
5. Other circumstances including, but not limited to, the following:  
 Poor control or persistent severe activation of secondary atopic disease (eg, AD, 
asthma)  
 Started on beta -blockers with no alternative medications available per the prescribing 
physician  
 Pregnancy  
6.1.3.2.  Anaphylaxis  
The definition of anaphylaxis that has been adopte d for this study is from the 2014 position paper 
by the European Academy of Allergy and Clinical Immunology (EAACI) Food Allergy and 
Anaphylaxis Guidelines Group ( Muraro, 2007 ), that in turn was based on the publications of 
Simons ( Simons, 2011 ) and  Johansson  (Johansson, 2004 ), and is consistent with the recently 
published “Internati onal consensus on (ICON) anaphylaxis” ( Simons, 2014 ).  Accordingly, 
anaphylaxis is defined as a severe, potentially life -threatening systemic hypersensitivity reaction, 
characterized by being rapid in onset with life -threatening airway, breathing, or circulatory 
problems that is usually, though not always, associated with skin and mucosal changes.  
When the diagnosis of anaphylaxis is made, the basis for having suspected the diagnosis must be 
document ed, using the criteria established by the Second Symposium on the Definition and 
Management of Anaphylaxis ( Sampson, 2006 ).  Reports of anaphylaxis will be collected in the 
electronic data capture ( EDC).  Reports of non -fatal and non -life-threatening anaphylaxis that do 
not require hospitalization (admitted for over 24 hours) will not require expedited safety reporting, 
as these are clinically anticipated events in the target population.  All reports  of anaphylaxis will 
be periodically reviewed to ensure proper patient care and prompt identification of any clinically 
concerning safety issues.  
6.2. Planned Interim Analysis  
No formal interim analysis is planned for this study.  
Data may be analyzed and reviewed internally by the sponsors.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 32 of 75 
CONFIDENTIAL  A primary analysis may be performed once all patients in the study have completed the 24 -week 
treatment  period as specified in the protocol (week 24 visit or earlier for those patients who are 
withdrawn prematurely from  the study). If performed, this primary analysis will be considered the 
final analysis for the primary endpoint and secondary efficacy endpoints up to week 24. A 
description of the statistical methods to be employed is in Section  11.4. 
6.3. Study Committees  
6.3.1.  Independent Data Monitoring Committee  
The dupilumab clinical development program in food allergy IDMC, composed of members who 
are independent  from the sp onsor and the study investigators, will provide oversight of patient 
safety by conducting formal reviews of accumulated safety data. The IDMC will provide 
Regeneron and Sanofi with appropriate recommendations on the conduct of the food allergy 
clinical stu dies to ensure the protection and safety of the patients enrolled in these studies.  
All activities and responsibilities of the IDMC are described in the IDMC charter.  
7. SELECTION, WITHDRAWA L, AND REPLACEMENT O F 
PATIENTS  
7.1. Number of Patients Planned  
Approximat ely 24 patients with a history of confirmed peanut allergy will be enrolled at 
approximately 10 sites in the US and Canada (CAN).  
7.2. Study Population  
Male and female pediatric patients ages 6 to 17 years inclusive with a history of peanut allergy 
confirmed by peanut SPT, sIgE, and by the amount of peanut protein (mg) safely ingested during 
a peanut DBPCFC.  
7.2.1.  Inclusion Criteria  
A patient must meet the following criteria to be eligible for inclusion in the study:  
1. Age 6 to 17 years (inclusive).  
2. Patient has a clinical history of allergy to peanuts or peanut -containing foods 
(symptom[s] of reaction due to exposure).  
3. Experience dose -limiting symptoms at or before the 100 mg challenge dose (≤144 mg 
cumulative) of peanut protein (measured as 200 mg of peanut f lour) on screening DBPCFC 
conducted in accordance with PRACTALL (Practical Issues in Allergology, Joint United 
States/European Union Initiative) guidelines. And not experiencing dose limiting symptoms 
to placebo  
4. Serum IgE to peanut of ≥10 kUA/L and/or a  SPT to peanut ≥8 mm compared to a 
negative control.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 33 of 75 
CONFIDENTIAL  5. Patients/legal guardians must be trained on the proper use of the epinephrine autoinjector 
device to be allowed to enroll in the study.  
6. Patients with other known food allergies must agree to elimin ate these other food items 
from their diet so as not to confound the safety and efficacy data from the study.  
7. Written informed consent from parent/guardian.  
8. Written assent from minor patients as appropriate (eg, above the age of 6 years or the 
applic able age per local regulatory requirements).  
9. Willing and able to comply with all clinic visits and study -related procedures.  
7.2.2.  Exclusion Criteria  
A patient who meets any of the following criteria will be excluded from the study:  
1. Any previous exposure to marketed dupilumab or dupilumab in a clinical trial  
2. Member of the clinical site study team or his/her immediate family  
3. History of other chronic disease (other than asthma, AD, or allergic rhinitis) requiring 
therapy (eg, heart disease, diabetes, hypertensi on) that, in the opinion of the Principal 
Investigator, would represent a risk to the patient’s health or safety in this study or the 
patient’s ability to comply with the study protocol  
4. History of frequent or recent severe, life -threatening episode of anap hylaxis or 
anaphylactic shock as defined by more than 3 episodes of anaphylaxis within the past 
year and/or an episode of anaphylaxis within 60 days of screening DBPCFC  
5. History of eosinophilic gastrointestinal disease  
6. History of eosinophilic granulomatosis  with polyangiitis  
7. Current participation or participation within 6 months prior to screening in any other 
interventional study.  
8. Severe, unstable asthma at time of enrollment or any patient with FEV1 <80% of 
predicted or ACQ >1.5.  
9. Use of systemic corticoste roids within 2 months prior to screening   
10. Use of omalizumab, benralizumab, or mepolizumab within 6 months prior to screening.  
11. Use of other forms of allergen immunotherapy (eg, oral, SC, patch or sublingual) or 
immunomodulatory therapy (not including corti costeroids) within 3 months prior to 
screening.  
12. Use of antihistamines within 5 days prior to screening and within 5 days prior to SPTs 
and day 1 of DBPCFCs.  
13. Use of any agents known or likely to interact with epinephrine (eg, beta blockers, ACE -
inhibitors, tri-cyclic antidepressants, or other drugs), within 3 weeks prior to screening.  
14. Allergy to oat (placebo in DBPCFC).  
15. Hypersensitivity to epinephrine and any of the excipients in the epinephrine product.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 34 of 75 
CONFIDENTIAL  16. History of a mast cell disorder, including mastocytosi s, urticarial pigmentosa, and 
hereditary or idiopathic angioedema.  
17. Treatment with a live (attenuated) vaccine within 3 months before the baseline visit and 
during the study  
18. Active chronic or acute infection requiring systemic treatment with antibiotics, a ntivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to the baseline visit. 
NOTE:  patients may be rescreened after the infection resolves.  
19. History of malignancy within 5 years before the screening visit, except completely 
treated  in situ carcinoma of the cervix, completely treated and resolved non -metastatic 
squamous or basal cell carcinoma of the skin.  
20. Established diagnosis of a primary immunodeficiency disorder (eg, Severe Combined 
Immunodeficiency, Wiskott Aldrich Syndrome, DiG eorge Syndrome, X -linked 
Agammaglobulinemia, Common Variable Immunodeficiency), or secondary 
immunodeficiency.  
21. Known history of human immunodeficiency virus (HIV) infection or HIV seropositivity 
at the screening visit.  
22. With an established diagnosis of hepa titis B viral infection at the time of screening or is 
positive for hepatitis surface antigen (HBsAg) or hepatitis core antibody (HBcAb) at the 
time of screening  
23. Body weight <20 kg  
24. Pregnant or breastfeeding women, women planning to become pregnant or bre astfeed 
during the study.  
25. Girls at or beyond menarche who are not sexually abstinent and are unwilling to practice 
highly effective contraception prior to the initial dose/start of the first treatment, during 
the study, and for at least 12 weeks after the last dose. Highly effective contraceptive 
measures include stable use of combined (estrogen and progestogen containing) 
hormonal contraception (oral, intravaginal, transdermal) or progestogen -only hormonal 
contraception (oral, injectable, implantable) asso ciated with inhibition of ovulation 
initiated 2 or more menstrual cycles prior to screening; intrauterine device (IUD); 
intrauterine hormone releasing system (IUS); bilateral tubal ligation; vasectomized 
partner; and or sexual abstinence.  
†Sexual abstinenc e is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatments. The 
reliability of sexual abstinence needs to be evaluated in relation to the durat ion of the clinical trial 
and the preferred and usual lifestyle of the patient.  
‡Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and lactational amenorrhoea method (LAM) are not acce ptable 
methods of contraception. Female condom and male condom should not be used together.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 35 of 75 
CONFIDENTIAL  7.3. Premature Withdrawal from the Study  
A patient  has the right to withdraw from the study at any time, for any reason, and without 
repercussion.  
The investigator and/or sponsor have the right to withdraw a patient from the study if it is no longer  
in the interest of the patient to continue in the study, or if the patient’s continuation in the study 
places the scientific outcome of the study at risk  (eg, if a patient does not or cannot follow study 
procedures). An excessive rate of withdrawals would render the study uninterpretable; therefore, 
unnecessary withdrawal of patients should be avoided.  
Patients who are withdrawn prematurely from the study will be asked to complete study 
assessments , as described in Section  9.1.2 . 
Rules for discontinuation of study treatment (permanent or temporary) ar e discussed in 
Section  8.3.2 . 
7.4. Replacement of Patients  
Patients prematurely discontinued from study will not be replaced.  
8. STUDY TREATMENTS  
8.1. Investigat ional and Reference Treatments  
Dupilumab 175 mg/mL (200mg dose): Each single -use, prefilled syringe delivers 200 mg of study 
drug (1.14 mL of a 175 mg/mL solution , expellable in 1mL syringe).  
Dupilumab 150 mg/mL (300mg dose): Each single -use, prefilled syr inge delivers 300 mg of 
study drug (2.0 mL of a 150 mg/mL solution , expellable in 2.25mL syringe).  
Subcutaneous injection sites of the study drug should be alternated among the different quadrants 
of the abdomen (avoiding navel and waist areas), upper thig hs, and upper arms so that the same 
site is not injected for 2 consecutive administrations.  
Instructions on dose preparation are provided in the pharmacy manual.  
8.1.1.  Peanut for Double -Blind Placebo -Controlled Food Challenge  
For the DBPCFC, peanut flour or plac ebo food challenge mixture will be administered in a food 
vehicle. Investigational sites will be provided with standardized recipes for preparation of the 
DBPCFC in a separate manual of procedures.  
8.2. Rescue Treatments  
If required, patients who experience all ergic reactions will be treated with IM or SC administration 
of epinephrine at the discretion of the clinical study personnel based on their own clinical 
judgement. The clinical  site will also collect rescue medications taken at home in the event of 
accidental exposure to peanut. For more details, see Section  6.1.2 . 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 36 of 75 
CONFIDENTIAL  8.3. Dose Mod ification and Study Treatment Discontinuation Rules  
8.3.1.  Dose Modification  
Dose modification for an individual patient is not allowed.  
8.3.2.  Study Drug Discontinuation  
Patients  who permanently discontinue from study drug and who do not withdraw from the study  
will be  asked to return  to the clinic for all remaining study visits per the visit schedule.  
Patients  who permanently discontinue from study drug and who opt to withdraw from the study 
will be asked to complete study assessments, per Section  9.1.2 . 
8.3.2.1.  Reasons for Permanent Discontinuation of Dupilumab and Food Challenge  
Study drug dosing will be permanently stopped in the event of:  
 Anaphylactic reaction or othe r severe systemic reaction to dupilumab  
 Any infection that is opportunistic, such as active tuberculosis and other infections 
whose nature or course may suggest an immuno -compromised status  
 Severe laboratory abnormalities that are deemed to be related to dupilumab:  
 Neutrophil count ≤0.5 x 103/µL 
 Platelet count ≤50 x 103/µL 
 ALT and/or AST values greater than 3 × ULN with total bilirubin >2 × ULN 
(unless elevated bilirubin is related to confirmed Gilbert’s Syndrome)  
 Confirmed AST and/or ALT >5 × ULN (for mor e than 2 weeks)  
 Diagnosis of a malignancy during the study  
 Evidence of pregnancy  
 Treatment with any prohibited concomitant medication or procedure  
 Missing ≥2 consecutive doses of study drug (dupilumab)  
8.3.2.2.  Reasons for Temporary Discontinuation of Dupilumab  
Study drug dosing will be temporarily discontinued in the event of:  
 Clinically important laboratory abnormalities such as:  
 ALT or AST 3 × ULN but ≤5 × ULN  
 CPK >2.5 x ULN  
 Serum creatinine >1.5 x ULN  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 37 of 75 
CONFIDENTIAL   Severe laboratory abnormalities (as noted in Section  8.3.2.1 ) where a causal 
relationship to dupilumab can be reasonably excluded (ie, an alternative cause is 
evident). In these cases, study treatment will be discontinued while the clinical 
circumstances are being assessed but it may be resumed when the laboratory 
parameters normalize sufficiently. A decision to resume treatment will be made 
jointly by the investigator and medical monitor.  
 Other intercurrent  illnesses or major surgery  
 An infection that requires parenteral treatment with antibiotic, antifungal, antiviral, 
antiparasitic, or antiprotozoal agents, or requires oral treatment with such agents for 
longer than 2 weeks.  
After  the condition leading to suspension of dosing normalizes sufficiently, study treatment may 
resume at the discretion of the principal investigator in consultation with the medical monitor. A 
decision to discontinue study drug and/or to reinstitute study treatment should be discusse d with 
the medical monitor. Note that dosing may NOT be resumed if patient met conditions for 
permanently discontinuing study drug described in Section  7.3 . The investigator may suspend 
study treatment at any time, even without consultation with the medical monitor, if the urgency of 
the situation requires immediate action and if this is determined to be in the patient’s best interest. 
However, the me dical monitor should be contacted as soon as possible in any case of study drug 
discontinuation. Resumption of study treatment after temporary discontinuation should always be 
discussed with the medical monitor.  
8.4. Management of Acute Reactions  
8.4.1.  Acute Injecti on Reactions  
8.4.1.1.  Systemic Injection Reactions  
Acute systemic  reactions following injection of study drug (SC) should be treated using clinical 
judgment to determine the appropriate response according to typical clinical practice.  
8.4.1.2.  Local Injection Site Reaction s 
Local injection site reactions must be reported as AEs and graded according to the Food and Drug 
Administration (FDA) September 2007 Guidance for Industry, Toxicity Grading Scale for Healthy 
Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (provided in the 
study Regulatory Binder, also see Section  10.5.1 ). 
8.5. Method of Treatment Assignment  
Approximatel y 24 patients will be enrolled using an interactive web response system (IWRS).  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 38 of 75 
CONFIDENTIAL  8.5.1.  Blinding  
This is an open -label study.  
For the DBPCFC, an unblinded pharmacist or designee will mix the peanut protein or oat protein 
in a chocolate food matrix that masks taste for administration in the DBPCFC. For each patient, a 
“blinded” evaluating  physician (Blinded Assessor) is to be desi gnated to assess the tolerability of 
the challenge doses presented in the DBPCFC. The blinded evaluating physician is not to be 
involved directly in the oversight of study product dosing or the assessment or management of 
AEs (for details refer to the Mask ing Plan).  To the extent practicable, the same blinded evaluating 
physician who determines dose limiting symptoms (DLS) in the screening DBPCFC should 
determine DLS in the week 24 and 36 DBPCFCs.  
8.6. Treatment Logistics and Accountability  
8.6.1.  Packaging, Labeling,  and Storage  
Study drug for injection will be provided as open -label kits. Each carton box will contain 1 labeled 
prefilled syringe. The c arton box and prefilled syringe label will indicate the protocol number, 
product identity and strength, medication/ref erence number, batch number, directions for use, 
route of administration, expiry date, sponsor information, and storage conditions, and will 
correspond to all regulatory requirements.  
Study drug will be stored at the site at a temperature of 2ºC to 8ºC; st orage instructions will be 
provided in the pharmacy manual.  
8.6.2.  Supply and Disposition of Treatments  
Study drug will be shipped at a temperature of 2ºC to 8ºC to the investigator or designee at regular 
intervals or as needed during the study. At specified time  points during the study (eg, interim site 
monitoring visits), at the site close -out visit, and following drug reconciliation and documentation 
by the site monitor, all opened and unopened study drug will be dest royed on site after approval 
from sponsor or  designee, or returned to a destruction depot after accountability and reconciliation.  
8.6.3.  Treatment Accountability  
All drug accountability records must be kept current.  
The investigator  must be able to account for all opened and unopened study drug. These re cords 
should contain the dates, quantity, and study medication  
 dispensed to each patient,  
 returned from each patient (if applicable), and  
 disposed of at the site or returned to the sponsor or designee.  
All accountability records must be made available for inspection by the sponsor and regulatory 
agency inspectors; photocopies  must be provided to the sponsor at the conclusion of the study.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 39 of 75 
CONFIDENTIAL  8.6.4.  Treatment Compliance  
All drug compliance records must be kept current and made available for inspection by the sponsor 
and regulatory agency inspectors.  
8.7. Concomitant Medications and Procedures  
Any treatment administered from  the time of the first dose of study drug to the final study visit 
will be considered  concomitant medication. This includes medications that were started  before the 
study and are ongoing during the study.  
The use of prohibited medications should only be considered when necessary for the patient's care 
and well -being  and when there are no other options.  Their use results in permanent treatment 
discontinuat ion but not discontinuation from study.   
8.7.1.  Prohibited Medications and Procedures  
Treatment with the following  concomitant medications is prohibited during the study:  
 Treatment with a live (attenuated) vaccine; below is a list of examples of such 
vaccines. R efer to study manual for a current, comprehensive list of prohibited 
vaccines  
Chickenpox (Varicella)  
FluMist -Influenza  
Intranasal influenza  
Measles (Rubeola)  
Measles -mumps -rubella combination  
Measles -mumps -rubella -varicella  combination  
Mumps  
Oral polio (Sabin)  Oral typhoid  
Rubella  
Smallpox (Vaccinia)  
Yellow fever  
Bacillus Calmette -Guerin  
Rotavirus  
Varicella Zoster (shingles)  
 Treatment with an investigational drug (other than dupilumab)  
 Treatment with immunomodulating biologic agents, including anti -IgE 
 Treatment with allergen immunotherapy  
 Treatment with systemic (oral, IV, IM, SC) corticosteroids for a duration of more 
than 5 continuous days, more than 15 days in total, or within 2 days prior to 
DBPCFCs  
 Treatment with any agents known or likely to inter act with epinephrine (eg, beta 
blockers, ACE -inhibitors, tri -cyclic antidepressants, or other drugs)  
 Treatment with antihistamines within 5 days prior to screening and within 5 days 
prior to SPTs and day 1 of DBPCFCs  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2 
 
 
Regeneron Pharmaceuticals, Inc .  Page 40 of 75 
CONFIDENTIAL  The following concomitant procedures are prohibited during study participation:   
 Major elective surgical procedures  
8.7.2.  Permitted Medications  
Other than the prohibited medications listed in Section  8.7.1 , treatment with concomitant 
medications is permitted  during the study.  
Medications used to treat chronic disease other than those listed in Section  8.7.1  are also permitted. 
Patients/ parents /caregivers should be advised not to reduce or stop taking medications for 
concomitant conditions throughout the entire study period. If there is any question re garding 
whether a concomitant medication may be used during the study, the study site should contact the 
medical monitor.  
9. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  
9.1. Schedule of Events  
Study assessments and procedures are presented by study period and visit i n Table  1. 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol   R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 41 of 75 
 CONFIDENTIAL  Table  1: Schedule of Events  
Study Procedure  Screening  Treatment Period  Follow -up UV ET 
Visit  V1 V1a V2 
Baseline  V3 phone  V4 clinic  V5 phone  V6 clinic  V7 phone  V8 clinic  V9 phone  V10 clinic  V11 phone  V12 clinic  V13 phone  EOT V14 
clinic  V15 EOS V16  if applicable  
 
Day -57 
to 
 -43 -42 
to 
 -15 1 15 29 43 57 71 85 99 113 127 141 155 169 211 253  
Week     2 4 6 8 10 12 14 16 18 20 22 24 30 36  
Visit Window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Screening/Baseline:                
Inclusion/Exclusion  X  X                 
Informed Consent/Assent  X                   
Medical History  X                   
Demographics  X                   
Enrollment    X                 
Epi injection training    X                 
Training on Study  Drug 
Administration    X                 
Treatment:                     
Administer Study Drug1   X X X X X X X X X X X X      
Study Drug 
Dispensation/Account   X  X  X  X  X  X  X     
Phone call to collect AEs, 
Conmeds and IP 
compliance     X  X  X  X  X  X      
Concomitant  Meds and Tx  X X X  X  X  X  X  X  X X X X X 
Efficacy5:                    
DBPCFC2, 3,4   X             X  X10   
Peanut SPT3 X                   
Titrated Peanut SPT3,7   X  X    X      X  X  X 
FAQLQ    X      X      X  X   
Safety:                     
Weight5 X  X  X  X  X  X  X  X X X X X 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol   R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 42 of 75 
 CONFIDENTIAL  Study Procedure  Screening  Treatment Period  Follow -up UV ET 
Visit  V1 V1a V2 
Baseline  V3 phone  V4 clinic  V5 phone  V6 clinic  V7 phone  V8 clinic  V9 phone  V10 clinic  V11 phone  V12 clinic  V13 phone  EOT V14 
clinic  V15 EOS V16  if applicable  
 
Day -57 
to 
 -43 -42 
to 
 -15 1 15 29 43 57 71 85 99 113 127 141 155 169 211 253  
Week     2 4 6 8 10 12 14 16 18 20 22 24 30 36  
Visit Window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Height5 X                   
Vital Signs5 X X X  X  X  X  X  X  X X X X X 
Physical Examination5 X X       X      X  X  X 
Spirometry6 X X       X      X  X  X 
Adverse Events5 X X X  X  X  X  X  X  X X X X X 
Laboratory Testing:                     
HIV Ab, HBsAg, HBcAb, 
Hep C Ab5  X                   
Hematology/Chemistry5 X  X      X      X  X X X 
FeNO Test6  X       X      X  X  X 
Pregnancy Test (WOCBP)5 S U U  U  U  U  U  U  U U S  U 
Urinalysis5 X X X      X      X  X X X 
Total IgE5   X      X      X  X  X 
Peanut sIgE, sIgG, and 
sIgG45 X  X  X  X  X  X    X X X  X 
Research Samples 
(serum/plasma)5  X X      X      X  X  X 
Blood samples for 
additional exploratory5 
research7    X      X      X  X  X 
PK/Drug Concentration 
and ADA Samples8:                    
PK/Drug conc. sample    X    X  X      X  X  X 
ADA sample    X      X      X  X  X 
Genomic DNA sample9:                    
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol   R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 43 of 75 
 CONFIDENTIAL  Study Procedure  Screening  Treatment Period  Follow -up UV ET 
Visit  V1 V1a V2 
Baseline  V3 phone  V4 clinic  V5 phone  V6 clinic  V7 phone  V8 clinic  V9 phone  V10 clinic  V11 phone  V12 clinic  V13 phone  EOT V14 
clinic  V15 EOS V16  if applicable  
 
Day -57 
to 
 -43 -42 
to 
 -15 1 15 29 43 57 71 85 99 113 127 141 155 169 211 253  
Week     2 4 6 8 10 12 14 16 18 20 22 24 30 36  
Visit Window (days)     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Buccal swab samples for 
DNA    X                 
WOCBP = women of childbearing potential  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 44 of 75 
CONFIDENTIAL  9.1.1.  Footnotes for the Schedule of Events Table  
1. Study drug will be administered in the clinic on day 1 by the study team, patient’s 
caregiver, or patient. With adequate training, study drug may be administered at home 
Q2W for the remaining injections. Patient/caregiver will complete an injection log to 
document compliance with injection of study drug and to document any AEs and 
concomitant medications.  
2. During DBPCFC, vital signs will be collected every 15 to 30 minutes.  After initial 
DBPCFC dose, only pulse and blood pressure need to be taken as part of safety 
monitoring.  
3. Patients should not take antihistamines within 5 days prior to SPTs and day 1 of the 
DBPCFCs.  
4. The food challenges (DBPCFC) will be performed on different days (1 day placebo [oat] 
protein, 1 day peanut protein, with order determined at random) at least 24 hours, but no 
more than 7  days, apart and not within 24 hours of a dose of study drug. After the last 
dose of the DBPCFC, the patient will be monitored for at least 2 hours and then 
discharged from the clinic.  
5. Assessments will be performed before the administration of study drug.  
6. FeNO measurement and spirometry will be performed on the same day, except for visit 1, 
in which only spirometry is performed. If the DBPCFC is scheduled on the day of the 
visit, then both FeNO measurement and spirometry will be performed twice before the 
patient goes home: once before DBPCFC, once after DBPCFC. FeNO should be done 
prior to spirometry.  
7. On the day of the DBPCFCs, blood draws for exploratory research, including TruCulture, 
basophil sensitivity, and peripheral blood mononuclear cells (PBMC) sam ples will be 
performed before the DBPCFC is performed. On the day of the DBPCFC, titrated SPTs 
will be performed before the DBPCFC.  
8. Samples for PK and ADA analysis should be collected prior to drug administration.  
9. Two buccal swabs for genomic analysis can  be collected on day 1 or any day after day 1.  
10. Only patients who passed a DBPCFC of at least 444 mg (cumulative) at week 24 will 
undergo a final DBPCFC (up to 2044 mg cumulative).  
9.1.2.  Early Termination Visit  
Patients who are withdrawn from the study before the  primary endpoint visit (week 24) will be 
asked to return to the clinic for study assessments described in Table  1. Patients who are withdrawn 
from the study after the primary endpoint visit will be asked to return to the clinic for early 
termination assessments only.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 45 of 75 
CONFIDENTIAL  9.1.3.  Unscheduled Visits  
All attempts  should be made to keep patients on the study schedule. Unscheduled visits may be 
necessary to repeat testin g following abnormal laboratory results, for follow -up of AEs, or for any 
other reason, as warranted.  
9.2. Study Procedures  
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  
The following  procedures will be performed for the sole purpose of determining study eligibility 
or characterizing the baseline population:  peanut SPT, HIV Ab, HBsAg, HBcAb, Hep C Ab, 
height. Demographics and medical history will be collected . 
9.2.2.  Efficacy Procedures  
9.2.2.1.  Double -Blind Placebo -Controlled Food Challenge  
The patient’s  sensitivi ty to peanut allergen is defined as the dose at which the patient experiences 
allergic reactions. All symptoms and signs will be evaluated and rated based on a standardized oral 
food challenge scoring system (see Appendix  2). Up -dosing during the DBPCFC will be stopped 
when the blinded assessor finds symptoms and/or signs that indicate a definite objective allergic 
reaction (CoFAR grading system (see Appendix  2) has occurred based on clinically significant 
changes in reported symptoms, physical findings, or vital signs that the patient is experiencing to 
the challenge material. The challenge will consist of 8 doses (peanut or placebo), given every 15 
to 30 minut es: 1, 3, 10, 30, 100, 300, 600, 1000 mg, up to 2044 mg peanut protein (cumulative). 
Both peanut and oat protein will be concealed in a food that masks the taste. The food challenges 
will be performed on different days (1 day placebo [oat] protein, 1 day p eanut protein, with order 
determined at random) at least 24 hours, but not more than 7 days, apart and not within 24 hours 
of a dose of study drug. After the last dose of the DBPCFC, the patient will be monitored for at 
least 2 hours and then discharged fr om the clinic.  Patients will be considered to have passed the 
DBPCFC if they do not experience any objective Grade 1 reaction by the CoFAR grading system 
(see Appendix  2). If the patient experiences reactions, they will be treated with the necessary 
rescue medications. Symptom severity will be adjudicated by an independent, blinded assessor 
who is not involved in performing the baseline food challeng e. 
9.2.2.2.  Peanut Skin Prick Test  
The standard SPT is performed on the volar surface of the patient’s forearm using standard whole 
peanut extract, 1:10 w/v (ALK -Abello) and will only be performed at screening. A positive result 
is ≥3 mm determined by averaging max imal perpendicular wheal diameters 15 minutes after 
applying the lancet. The positive control is histamine base, 6 mg/mL (ALK -Abello) and with a 
wheal ≥3 mm indicating a valid test. The negative control is glycerol saline.  
The titrated SPT is the skin tes ting for atopic response at different concentrations of peanut extract 
with saline as negative control and histamine as positive controls. The test will be performed at 
time points shown in Table  1. The SPTs will be performed starting at the following dilutions: neat, 
1:20, 1:200, 1:2000, 1:20,000. Wheal size induced by peanut extract at each concentration will be 
calculated as the average of the largest  diameter and the perpendicular midpoint diameter.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 46 of 75 
CONFIDENTIAL  9.2.2.3.  Food Allergy Quality of Life Questionnaire  
The Food Allergy Quality of Life Questionnaire (FAQLQ) is a validated food allergy -specific 
health -related quality of life (HRQL) questionnaire, which measures th e impact of social and 
dietary limitations and assesses the emotional impact of these restrictions on the lives of patients.   
Patients self -report the impact of food allergy on HRQL using different forms of FAQLQ 
depending on their age; the child form (FAQLQ -CF) is used by patients aged 8 to 12 years and the 
teenager form (FAQLQ -TF) is used for patients aged 13 to 17 years.  The parent form (FAQLQ -
PF) is a measure of children’s HRQL that is reported by parent proxy from the child’s perspective 
and can be used for patients of ages 0 to 12 years.  The FAQLQ will be administered to patients 
and, when appropriate, parents at time poin ts in accordance with Table  1. Patients will continue 
using the FAQLQ version first administered at baseline regardless of moving to the next age 
brack et. 
9.2.3.  Safety Procedures  
9.2.3.1.  Vital Signs  
Vital signs, including temperature, sitting blood pressure, pulse, and respiration will be collected 
at time points  according to Table  1. During the DBPCFC, vital signs will be monitored every 15 
to 30 minutes. After initial DBPCFC dose, only pulse and blood pressure need to be taken as part 
of safety monitoring.  
9.2.3.2.  Physical Examination  
A thorough and complete physical exami nation will be performed at time points according to 
Table  1.  Care should be taken to examine and assess any abnormalities that may be present, as 
indicated by the patient’s medical history.  
9.2.3.3.  Spirometry  
A spirometer that meets the American Thoracic Society (ATS) / European Respiratory Society 
(ERS) recommendations will be used to measure FEV1 and/or PEFR. During DBPCFC, 
spirometry should  be performed before and after the challenge. The same spirometer and standard 
spirometric techniques, including calibration, should be used to perform spirometry at different 
visits and, whenever possible, the same person should perform the measurements. FeNO should 
be done prior to spirometry.  
9.2.3.4.  Laboratory Testing  
Hematology, chemistry, urinalysis, and pregnancy testing samples will be analyzed by a central 
laboratory. Detailed instructions for blood sample collection are in the laboratory manual provided 
to study sites.  
Samples for laboratory  testing will be collected at visits according to Table  1. Tests will include:  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 47 of 75 
CONFIDENTIAL  Blood Chemistry  
Sodium  Total protein, serum  Total bilirubin  
Indirect bilirubin  
Potassium  Creatinine  Total cholesterol*  
Chloride  Blood urea nitrogen (BUN)  Triglycerides  
Carbon dioxide  Aspartate aminotransferase (AST)  Uric acid  
Calcium  Alanine aminotransferase (ALT)  Creatine phosphokinase (CPK)  
Glucose  Alkaline phosphatase   
Albumin  Lactate dehydrogenase (LDH)   
 
*(low -density lipoprotein [LDL] and high -density lipoprotein [HDL])  
Hematology  
Hemoglobin  Differential:  
Hematocrit   Neutrophils  
Red blood cells (RBCs)   Lymphocytes  
White blood cells (WBCs)   Monocytes  
Red cell indices   Basophils  
Platelet count   Eosinophils  
Urinalysis  
Color  Glucose  RBC  
Clarity  Blood  Hyaline and other casts  
pH Bilirubin  Bacteria  
Specific gravity  Leukocyte esterase  Epithelial cells  
Ketones  Nitrite  Crystals  
Protein  WBC  Yeast  
Other Laboratory Tests  
For female patients of child -bearing potential, a serum pregnancy test will be performed at 
screening  and end of study visits. For other visits where a pregnancy test is scheduled, a urine 
pregnancy test will be performed.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 48 of 75 
CONFIDENTIAL  Abnormal Laboratory Values and Laboratory Adverse Events  
All laboratory  values must be reviewed by the investigator or authorized designee.  
Significantly abnormal test results that occur after start of treatment must be repeated to confirm 
the nature and degree of the abnormality. When necessary, appropriate ancillary investigations 
should be initiated. If the abnormality fails to resolve or cannot be explained by events or 
conditions unrelated to the study medication or its administration, the Medical/Stud y Director must 
be consulted.   
The clinical significance of an abnormal test value, within the context of the disease under study, 
must be determined  by the investigator.  
Criteria for reporting laboratory values as an AE are provided in Section  10.4.5 . 
9.2.4.  Drug Concentration and Measurements  
Samples for drug concentration will be collected at time points listed in Table  1. 
Any unused samples may be used for exploratory biomarker research.  
9.2.5.  Immunogenicity Measurements and Samples  
Samples for ADA assessment will be collected at time points liste d in Table  1. 
Detailed instructions for blood sample collection are included in the laboratory manual provided 
to study sites. Any unused samples may be  used for exploratory research.  
9.2.6.  Pharmacodynamic and Exploratory Biomarker Procedures  
Biomarker samples will be collected at time points according to Table  1. Biomarker measurements 
will be performed  to determine effects on relevant physiological and pathogenic processes.  
The biomarkers studied will be ones believed to be relevant to the pathophysiology of peanut 
allergy, immunology, mechanism of action of  dupilumab and possible toxicities. Biomarkers 
studied may include but need not be limited to: Total IgE, TARC, sIgE, sIgG4, sIgG, TruCulture 
study of ex vivo peanut stimulation of whole blood (supernatant cytokine and chemokine profiling, 
mRNA analyses [i ncluding transcriptome sequencing] of the resulting cell pellet), and basophil 
allergen sensitivity to allergen stimulation and peanut -specific T -cell and Th2A subset profiling. 
Additional serum and plasma samples will be banked for research. Any unused sa mples collected 
for PK, ADA, and biomarkers may also be used for exploratory research.  
Exploratory biomarker results not required for protocol -defined endpoint analyses will not be 
included in the clinical study report.  
9.2.6.1.  Serum Thymus and Activation -Regulate d Chemokine and Total IgE  
Serum TARC and total IgE are markers of Type 2 activity. Dupilumab significantly suppressed 
both TARC and total IgE in studies of adult AD, nasal polyposis, and asthma patients.  
9.2.6.2.  Serum Peanut -Specific Antibody Assays (Peanut -specific IgE, IgG, IgG4)  
In prior dupilumab studies, dupilumab suppressed both total and allergen -specific IgEs. In general, 
dupilumab suppresses total IgE by ~ 50% within 12 to 16 weeks of treatment initiation.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 49 of 75 
CONFIDENTIAL  9.2.6.3.  Fractional Exhaled Nitric Oxide  
Fractional exhaled nitric oxide (FeNO) is a non -invasive marker that has been shown to correlate 
with allergic airway  inflammation and IgE sensitization. The measurement of FeNO was reported 
to be predictive of peanut oral food challenge outcome ( Preece, 2014 ). Although no manufacturer 
has validated the FeNO device for children under 7 years old due to inadequate exhalation force, 
there are no contraindications with the use of FeNO for 6 -year-old children.  Also, specific 
guidance and reference ranges are available for collection in children as young as 6 years of age 
(Brody, 2013 ) (Menou, 2017 ). As FeNO is an exploratory biomarker, it will be collected for 
children 6 years old unless the investigator declines to collect. Fractional exhaled nitric oxide will 
be performed prior to spirometry.  
9.2.7.  Exploratory Research  
Research samples (whole blood/PBMCs) will be banked, unless th ere are local regulatory or IRB 
restrictions at the study  site, for exploratory research related to immunology of peanut allergy, 
other allergic diseases, IL -4/IL-13-mediated Type 2 inflammation, and dupilumab (including 
mechanism of action, efficacy, toxi city).  Research may also include, T -cell and B -cell receptor 
repertoire analyses, which requires RNA sequencing). The list may be altered or expanded as it is 
recognized that more relevant or novel biomarkers may be discovered during the course of this 
study. Banked research samples (serum/plasma/PBMCs), as well as any unused samples for study -
related research (including PK and ADA samples), will be stored for up to 15 years after the final 
date of the database lock.  The unused samples may be utilized for  the scope of research described 
above.  After 15 years, any residual samples will be destroyed. Results of these exploratory 
analyses will not be reported in the CSR.  
9.2.7.1.  Genomics Analysis  
DNA samples will be collected for the genomics analyses unless there a re local regulatory or IRB 
restrictions at the study site. Samples will be single -coded as defined by the International Council 
for Harmonisation (ICH) guideline E15. Samples will be stored for up to 15 years after the final 
date of the database  lock and m ay be used for research purposes. The purpose of the genomic 
analyses is to identify genomic associations with clinical or biomarker response, other clinical 
outcome measures and possible AEs. In addition, associations between genomic variants and 
prognosi s or progression of peanut allergy, as well as related diseases may also be studied. Samples 
may also be used as controls in genetic research unrelated to the scientific purposes stated above. 
Patient's genetic data may be used or combined with data collec ted from other studies to identify 
and validate genomic markers related to the study drug and related diseases. Analyses may include 
sequence determination or single nucleotide polymorphism studies of candidate genes and 
surrounding genomic regions. Other methods, including whole -exome sequencing, whole -genome 
sequencing, DNA copy number variation, and transcriptome sequencing (eg, TruCulture cell 
pellet) may also be performed. The list of methods may be expanded to include novel methodology 
that may be dev eloped during the course of this study or sample storage period. Results from the 
genomic analysis will not be reported in the CSR.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 50 of 75 
CONFIDENTIAL  10. SAFETY DEFINITIONS, REPORTING, AND MONIT ORING  
10.1. Obligations of Investigator  
The investigator must promptly report to the Institutional Review Board (IRB)/Ethics Committee 
(EC) all unanticipated problems involving risks to patients, according to local regulations. This 
may include death from any cause and all SAEs related to the us e of the study drug. It is 
recommended that all SAEs be reported to the IRB/EC, according to local regulations.  
10.2. Obligations of Sponsor  
During the course of the study, the sponsor will report in an expedited manner all SAEs that are 
both unexpected and at l east reasonably related to the study drug (suspected unexpected serious 
adverse reaction [ SUSAR ]), to the health authorities, IRBs/ECs as appropriate, and to the 
investigators.  
Any AE not listed as an expected event in the Reference Safety Information sec tion of the 
Investigator’s Brochure will be considered as unexpected. Any worsening of or new onset of 
symptoms related to (add underlying condition intended to be studied) which occur during the 
screening/washout period prior to study drug administration will be considered expected.  
In addition, the sponsor  will report in all other SAEs to the health authorities, according to local 
regulations.  
At the completion of the study, the sponsor will report all safety observations made during the 
conduct of the trial in the clinical study report to health authorities and IRB/ECs as appropriate.  
10.3. Definitions  
10.3.1.  Adverse Event  
An AE is any untoward medical occurrence in a patient administered a study drug, which may or 
may not have a causal relationship with the study dru g. Therefore, an AE is any unfavorable and 
unintended sign (including abnormal laboratory finding), symptom, or disease, which is 
temporally associated with the use of a study drug, whether or not considered related to the study 
drug.  
An AE also includes a ny worsening (ie, any clinically significant change in frequency and/or 
intensity) of a pre -existing condition  that is temporally associated with the use of the study drug.  
10.3.2.  Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose:  
 Results in death  – includes all deaths, even those that appear to be completely 
unrelated to study drug (eg, a car accident in which a patient is a passenger).  
 Is life-threatening  – in the view of the investigator, the patient is at immediate risk of 
death  at the time of the event. This does not include an AE that had it occurred in a 
more severe form, might have caused death.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 51 of 75 
CONFIDENTIAL   Requires in -patient hospitalization  or prolongation of existing hospitalization .  In-
patient hospitalization is defined as admission  to a hospital (any duration) or an 
emergency room visit for longer than 24 hours. Prolongation of existing 
hospitalization is defined as a hospital stay that is longer than was originally 
anticipated for the event, or that is prolonged due to the developm ent of a new AE as 
determined by the investigator or treating physician.  
 Results in persistent or significant disability/incapacity  (substantial disruption of 
one’s ability to conduct normal life functions).  
 Is a congenital anomaly/birth defect  
 Is an impo rtant medical event - Important medical events may not be immediately 
life-threatening or result in death or hospitalization, but may jeopardize the patient or 
may require intervention to prevent one of the other serious outcomes listed above 
(eg, intensiv e treatment in an emergency room or at home for allergic bronchospasm; 
blood dyscrasias or convulsions that do not result in hospitalization; or development 
of drug dependency or drug abuse).  
10.3.3.  Adverse Events of Special Interest  
An adverse event of special i nterest (AESI; serious or non -serious) is one of scientific and medical 
concern specific to the sponsor’s product or program, for which ongoing monitoring and rapid 
communication  by the investigator to the sponsor can be appropriate. Such an event might wa rrant 
further investigation in order to characterize and understand it. Depending on the nature of the 
event, rapid communication by the trial sponsor to other parties (eg, regulators) might also be 
warranted (Section  10.4.3 ). 
10.4. Recording and Reporting Adverse Events  
10.4.1.  Adverse Events  
The investigator (or designee) will record all AEs that occur from the time the informed consent 
is signed until the end of  study. However, allergic reactions to the DBPCFC during the screening 
phase, at endpoint challenges  (at week  24 and 36) will be recorded as allergic signs and symptoms 
since they are anticipated to allergen. Refer to the study reference manual for the pro cedures to be 
followed.  
Information on follow -up for AEs is provided in Section  10.4.6 . Laboratory, vital signs 
abnormalities are to be recorded as AEs as outlined in Section  10.4.5 . 
10.4.2.  Serious Adverse Events  
All SAEs, regardless of assessment of causal relationship to study drug, must be reported to the 
sponsor (or designee ) within 24 hours. Refer to the study reference manual for the procedure to be 
followed.  
Information not available at the time of the initial report must be documented in a follow -up report. 
Substantiating  data such as relevant hospital or medical records and diagnostic test reports may 
also be requested.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 52 of 75 
CONFIDENTIAL  In the event the investigator is informed of an SAE after the patient completes the  study, the 
following will apply:  
 SAE with an onset within 30 days of the end of study or within 12 weeks of last study 
drug administration if the patient early terminated from the study - the SAE will be 
reported to the sponsor. The investigator should ma ke every effort to obtain follow -up 
information on the outcome until the event is considered chronic and/or stable.  
 SAE with an onset day greater than 30 days from the end of study/early termination 
visit - only fatal SAEs and those deemed by the investiga tor to be drug -related SAEs 
will be reported to the sponsor. The investigator should make every effort to obtain 
follow -up information on the outcome of a drug -related SAE until the event is 
considered chronic and/or stable.  
10.4.3.  Other Events that Require Accel erated Reporting to Sponsor  
The following events also require reporting to the sponsor (or designee) within 24 hours of learning 
of the event : 
Symptomatic Overdose of Study Drug:  Dupilumab  is administered every 14±3 days Q2W. The 
doses of this investigatio nal product must be separated by ≥11 days to avoid overdose. Accidental 
or intentional overdose of at least 2  times the intended dose of study drug within the intended 
therapeutic window, if associated with an A E. 
Pregnancy: Although pregnancy is not consid ered an AE, it is the responsibility of the investigator  
to report to the sponsor (or designee), within 24  hours of identification, any pregnancy occurring 
in a female  during the study or within  12 weeks of the last d ose of study drug. Any complication 
of pregnancy affecting a female study patient and/or fetus and/or newborn that meets the SAE 
criteria must be reported as an SAE. Outcome for all pregnancies should be reported to the sponsor.  
Adverse Events of Special I nterest:   All AESI, serious and nonserious, must be reported within 
24 hours of identification using the same reporting process as for SAE reporting, per 
Section  10.4.2 . Adverse events of special interest for this study include the following:   
 Anaphylactic reactions  
 Systemic or extensive hypersensitivity reactions  
 Malignancy  
 Helminthic infections  
 Suicide -related events  
 Conjunctivitis (any type or etiology), keratitis or blepharitis (for all these AEs only 
events that are severe or serious or lasting ≥4 weeks will be reported as AESIs)  
Refer to the study manual for the procedures to be followed.  
10.4.4.  Reporting Adverse Events Leading to Withdrawal from th e Study  
All AEs that lead to a patient’s withdrawal from the study must be reported to the sponsor’s 
Medical/Study Director within 30 days.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 53 of 75 
CONFIDENTIAL  Refer to the study reference manual for the procedures to be followed.  
10.4.5.  Abnormal Laboratory, Vital Signs Results  
The criteria for determining  whether an abnormal objective test finding should be reported as an 
AE include:  
 the test result is associated with accompanying symptoms, and/or  
 the test result requires additional diagnostic testing or medical/surgical interventio n, 
and/or  
 the test result leads to a change in dosing (outside of protocol -stipulated dose 
adjustments), discontinuation from the study, significant additional concomitant drug 
treatment, or other therapy  
Contact the Medical/Study Director in the event the  investigator feels  that an abnormal test finding 
should be reported as an AE, although it does not meet any of the above criteria.  
Repeating an abnormal test, in the absence of any of the above conditions, does not constitute an 
AE. Any abnormal  test resu lt that is determined to be an error does not require reporting as an AE.  
Evaluation of severity of laboratory abnormalities will be assessed according to the scale outlined 
in Section  10.5.1 . 
10.4.6.  Follow -up 
Adverse  event information will be collected until the patient’s last study visit.  
Serious adverse event  information will be collected until the event is considered chronic and/or 
stable.  
10.5. Evaluation of Severity and Causality  
10.5.1.  Evaluation of Severity  
The severity of AEs will be graded according to the following scale:  
Mild:  Does not interfere in a significant manner with the patient normal functioning level.  It may 
be an annoyance . Prescription drugs are not ordinarily needed for relief of symptoms, but may be 
given because of personality of the patient.  
Moderate:   Produces some impairment of functioning but is not hazardous to health.  It is 
uncomfortable  or an embarrassment. Treatment for symptom may be needed.  
Severe:   Produces significant impairment of functioning or incapacitation and is a definite hazard 
to the patient’s health.  Treatment for symptom may be given and/or patient hospitalized.  
If a laboratory value is considered an AE, its severity sho uld be based on the degree of 
physiological impairment the value indicates.  
Injection Site Reactions  
The severity of injection site reactions will be graded according to the following scale (semi -colon 
indicates “or” within description of grade:  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 54 of 75 
CONFIDENTIAL  Mild :  Pain that does not interfere with activity; mild discomfort to touch; <5 cm of erythema or 
induration that does not interfere with activity  
Moderate :  Pain that requires repeated use of non -narcotic pain reliever >24 hours or interferes 
with activity; disc omfort with movement; 5.1 cm to 10 cm erythema or induration or induration 
that interferes with activity  
Severe :  Pain that requires any use of narcotic pain reliever or that prevents daily activity; 
significant discomfort at rest; >10 cm erythema or indur ation; prevents daily activity; requires ER 
visit or hospitalization; necrosis or exfoliative dermatitis  
10.5.2.  Evaluation of Causality  
Relationship of Adverse Events to Dupilumab:  
The relationship of AEs to study drug will be assessed by the investigator, and wi ll be a clinical 
decision based on all available information. The following question will be addressed:  
Is there a reasonable possibility that the AE may have been caused by the study drug?  
The possible answers are:  
Not Related:  There is no reasonable poss ibility that the event may have been caused by 
the study drug  
Related:  There is a reasonable possibility that the event may have been caused by the study 
drug 
The investigator should justify the causality assessment of each SAE.  
A list of factors to consid er when assessing the relationship of AEs to study drug is provided below.  
Please note that t his list is not exhaustive.  
Is there a reasonable possibility that the event may have been caused by the study drug?  
No: 
 due to external causes such as environmental factors or other treatment(s) being 
administered  
 due to the patient’s disease state or clinical condition  
 do not follow a reasonable temporal sequence following the time of administration of 
the dose of study drug  
 do not reappear or worsen wh en dosing with study drug is resumed  
 are not a suspected response to the study drug based upon preclinical data or prior 
clinical data  
Yes: 
 could not be explained by environmental factors or other treatment(s) being 
administered  
 could not be explained by t he patient’s disease state or clinical condition  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 55 of 75 
CONFIDENTIAL   follow a reasonable temporal sequence following the time of administration of the 
dose of study drug  
 resolve or improve after discontinuation of study drug  
 reappear or worsen when dosing with study drug  
 are known or suspected to be a response to the study drug based upon preclinical data 
or prior clinical data  
10.6. Safety Monitoring  
The investigator will monitor the safety of study patient at his/her site(s) as per the requirements 
of this protocol and consiste nt with current Good Clinical Practice (GCP). Any questions or 
concerns should be discussed  with the sponsor in a timely fashion. The sponsor will monitor the 
safety data from across all study sites. The Medical/Study Director will have primary responsibil ity 
for the emerging safety profile of the compound, but will be supported by other departments (eg, 
Pharmacovigilance and Risk Management; Biostatistics and Data Management). Safety 
monitoring will be performed on an ongoing basis (eg, individual review o f SAEs) and on a 
periodic cumulative aggregate basis.  
10.7. Investigator Alert Notification  
Regeneron (or designee) will inform all investigators participating in this clinical trial, as well as 
in any other clinical trial using the same investigational drug, of any SAE that meets the relevant 
requirements for expedited reporting (an AE that is serious, unexpected based on the reference 
safety information in the Investigator’s Brochure, and has a reasonable suspected causal  
relationship to the study drug).  
11. STATISTICAL PLAN  
This section provides the basis for the statistical analysis plan (SAP) for the study.  The SAP may 
be revised during the study to accommodate  amendments to the clinical study protocol and to make 
changes to adapt to unexpected issues in study execution and data that may affect the planned 
analyses. The final SAP will be issued before the database is locked.  
Analysis variables are listed in Section  5. 
11.1. Statistical Hypothesis  
The statistical hypothesis is on the primary endpoint, the proportion of patients who achieve a 
cumulative dose of at least 444 mg peanut protein during a DBPCFC at week 24.  
Let μ D be the true proportion  of patients who achieve a cumulative dose of at least 444 mg peanut 
protein during a DBPCFC at week 24 for dupilumab. The following hypothesis for the superiority 
testing will be tested at the 2 -sided 5% significance level:  
Null hypoth esis H0: μ D = 8%, ie, the proportion of patients who achieve a cumulative dose of at 
least 444 mg peanut protein during a DBPCFC at week 24 is 8%.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 56 of 75 
CONFIDENTIAL  Alternative hypothesis Ha: μ D ≠ 8%, ie, the proportion of patients who achieve a cumulative dose 
of at least  444 mg peanut  protein during a DBPCFC at week 24 is different from 8%.  
11.2. Justification of Sample Size  
The sample size is determined to adequately power the primary endpoint of the proportion of 
patients who pass at least a DBPCFC of at least 444 mg (cumulat ive) of peanut protein at week 
24. Based on assessment of clinical data from  the Aimmune Therapeutics AR101 phase 3 study, 
it is assumed that the rate of a tolerated cumulative dose of at least 444  mg of peanut protein on 
DBPCFC at week 24 is 29% in dupilu mab and 8% in placebo ( Vickery, 2018 ). 
A sample size of 20 patients will have 80% power to detect the 29% tolerated rate in dupilumab 
group at the 2 -sided 5% significance level. Allowing for a dropout rate of around 15%, 
approximately 24 patients will be required. The sample size calculations were done by one -sample 
Chi-square test (normal approximation) usi ng nQuery + nTerim 4.  
11.3. Analysis Sets  
11.3.1.  Efficacy Analysis Sets  
The full analysis set (FAS) includes all enrolled patients. The week 36 FAS includes patients who 
pass a DBPCFC of at least 444 mg (cumulative) of peanut protein at week 24.  
11.3.2.  Safety Analysis Set  
The safety analysis set (SAF) includes all patients who received any study drug; it is based on the 
treatment received (as treated). Treatment compliance/administration and all clinical safety 
variables will be analyzed using the SAF.  
11.3.3.  Pharmacokinetic Analysis  Sets 
The PK population includes all treated patients who received any study drug and who had at least 
1 non -missing drug concentration result following the first dose of study drug.  
11.3.4.  Immunogenicity Analysis Sets  
The ADA  analysis set consists of all patient s who received any study drug and who had at least 1 
non-missing ADA result following the first dose of study drug.  
The NAb analysis set includes all patients who received any study drug and who are negative in 
the ADA assay or with at least 1 non -missing  result in the NAb assay (patients who are ADA 
negative are set to negative in the NAb analysis set).  
11.4. Statistical Methods  
For continuous variables, descriptive statistics will include the following information:  the 
number of patients reflected in the calc ulation (n), mean, median, first quartile (Q1), third 
quartile (Q3), standard deviation, minimum, and maximum.   
For categorical  or ordinal data, frequencies and percentages will be displayed for each category.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 57 of 75 
CONFIDENTIAL  All dupilumab  patients, regardless of whether  it is 200 mg dupilumab  or 300 mg dupilumab, will 
be combined for analysis.  
11.4.1.  Patient Disposition  
The following will be provided:  
 The total number of screened patients:  met the inclusion criteria regarding the target 
indication and signed the informed conse nt form (ICF)  
 The total number of enrolled patients  
 The total number of patients in each analysis set (eg, FAS, provided in Section  11.3 
for analysis sets)  
 The total number of patients who discontinued the study, and the reasons for 
discontinuation  
 A listing of patients prematurely discontinued from treatment, along with reasons for 
discontinuation  
11.4.2.  Demography and Baseline Characteristics  
Demographic and baseline characteristics will be summarized descriptively.   
11.4.3.  Efficacy Analyses  
Efficacy analyses will be conducted using the FAS population and week 36 FAS population. The 
FAS will be used for efficacy analysis at week 24, and week 36 FAS wi ll be used for efficacy 
analysis at week 36.  
11.4.3.1.  Primary Efficacy Analysis  
The FAS will be used for the primary efficacy endpoint. The primary endpoint will be analyzed 
using one -sample Chi -square test. Estimate of proportion, p -value, and the 2 -sided 95% 
confidence interval will be provided.  
If a patient does not have available DBPCFC data at week 24, the patient will be considered as a 
non-responder regardless of reasons for missing data.  
Sensitivity analyses of the primary endpoint will include an analys is of the subset of patients 
with available week 24 DBPCFC. Other sensitivity analyses may be proposed in the SAP.  
Subgroup analysis (eg, by baseline weight group) will be performed.  
11.4.3.2.  Secondary Efficacy Analysis  
All secondary endpoints (Section  4.1.2 ) will be analyzed descriptively at given visits. FAS will be 
used for efficacy analysis at week 24, and week 36 FAS will be used for efficacy analysis at w eek 
36. 
All secondary endpoints will be analyzed descriptively at given visits. FAS will be used for 
efficacy analysis at week 24, and week 36 FAS will be used for efficacy analysis at week 36. For 
binary endpoints, the analysis and imputation methods will  be similar to the primary analysis.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 58 of 75 
CONFIDENTIAL  A one -sample t -test will be performed to assess the change from baseline to week 24 in the 
cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC. Estimate of 
change from baseline to week 24, p -value, and the 2 -sided 95% confidence interval will be 
provided. If the data is extremely skewed, nonparametric method may be applied. Details will be 
provided in the SAP. The missing data will be imputed by the last non -missing DBPCFC 
assessment including b aseline.  
For other continuous endpoints, the analysis and imputation methods will be applied similarly.  
Sensitivity analysis will include an analysis based on the observed cases. Other sensitivity analysis 
may be proposed in the SAP.  
11.4.3.3.  Multiplicity Considera tions  
No adjustments for multiplicity for the secondary endpoints are planned for this study.  
11.4.3.4.  Timing of Analyses  
A primary analysis may be performed when the last patient completes 24 weeks of the treatment 
period as specified in the protocol (week 24 visi t or earlier for those patients who are withdrawn 
prematurely from the study).  No changes in the conduct of the study will be made based on this 
primary analysis.  The analyses of primary and secondary endpoints up to week 24 as specified in 
Section  11.4.3.1  and Section  11.4.3.2  will be the final analysis of the primary endpoint and the 
secondary endpoints up to week 24.   
11.4.4.  Safety Analysis  
11.4.4.1.  Adverse Events  
Definitions  
For safety variables, 2 observation periods are defined:  
 The pretreatment period is defined as the time from signing  the ICF to before the first 
dose of study drug.  
 The treatment -emergent period is defined as the day from first dose of study drug to 
the end of the study. The treatment -emergent period includes the 24 -week treatment 
period and follow -up period  
Treatment -emergent adverse events are defined as those that are not present at baseline or represent 
the exacerbation of a pre -existing condition during the treatment -emergent period.  
Analysis  
All AEs reported in this study will be coded using the currently available  version of the Medical 
Dictionary for Regulatory  Activities (MedDRA®). Coding will be to lowest level terms. The 
verbatim text, the preferred term (PT), and the primary system organ class (SOC) will be listed.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 59 of 75 
CONFIDENTIAL  Summaries of all TEAEs will include:  
 The number (n) and percentage (%) of patients with at least 1 TEAE by SOC and PT  
 TEAEs by severity (according to the grading scale outlined in Section  10.5.1 ), 
presented by SOC and PT  
 TEAEs by relationship to treatment (related, not related), presented by SOC and PT  
 Treatment -emergent AESIs (defined with a PT or a prespecified grouping)  
Deaths and other SAEs will be listed and summarized.  
Treatment -emergent adverse events leading to permanent treatment discontinuation will be listed 
and summarized.  
11.4.4.2.  Other Safety  
Vital Signs  
Vital signs (temperature, pulse, blood pressure, and respiration rate) will be summarized by 
baseline and change from baseline to ea ch scheduled assessment time as well as the vital signs 
according to Bock’s scale during the challenge ( Appendix  2) with descriptive statistics.  
Laboratory Tests  
Laboratory test results will be summarized by baseline and change from baseline to each scheduled  
assessment time with descriptive statistics.  
Number and percentage of patients with a potentially clinically significant value (PCSV) at any 
time point will be summarized for each clinical laboratory test.  
Shift tables based on baseline normal/abnormal and other tabular and graphical methods may be 
used to present  the results for laboratory tests of interest.  
Listings will be provided with fla gs indicating the out of laboratory range values.  
11.4.4.3.  Treatment Exposure  
The duration of exposure during the study will be presented and calculated as:  
(Date of last study drug injection – date of first study drug injection) + 14 days  
The number (%) of patient s exposed to the study drug will be presented by specific time periods. 
The time periods  of interest will be specified in the SAP.  
In addition, duration  of exposure during the study will be summarized using number of patients, 
means, standard deviation, mi nimums, Q1, medians, Q3, and maximums.  
A summary of the number of doses will be provided.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 60 of 75 
CONFIDENTIAL  11.4.4.4.  Treatment Compliance  
The compliance with study treatment will be calculated as follows:  
 Treatment Compliance of study drug = (Number of study drug injections during 
exposure period)/(Number of planned study drug injections during exposure period) × 
100%  
The treatment compliance  of study drug will be presented by specific ranges. The ranges of interest 
will be specified in the SAP.  
11.4.5.  Analysis of Drug Concentration Data  
Descriptive statistics will be used to summarize the concentration data at each sampling time.  
No formal statistical analysis will be performed.  
11.4.6.  Analysis of Immunogenicity Data  
Analysis of ADA will be conducted on samples collected at baseline, week 12, week 24, and week 
36. Samples that are positive in the ADA assay will be further characterized for ADA titers and 
for the presence of an NAb response.  
Anti-drug antibody response categories and titer  categories that will be assessed are as follows:   
 Pre-existing immunoreactivity  
 Treatment -emergent response  
The treatment -emergent responses will be further characterized as persistent, 
indeterminate, and transient.  
 Treatment -boosted ADA response  
 Titer value category (tier range)  
 Low (titer <1,000)  
 Moderate (1,000≤ titer ≤10,000)  
 High (titer >10,000)  
 NAb response in ADA positive patients.  
Listings of pre -existing, treatment -boosted, and treatment -emergent ADA responses, ADA titers 
and NAb positivity  presented by patient, time point, and dose group cohort/group will be provided. 
Incidence of treatment -emergent ADA and NAb will be assessed as absolute occurrence (N) and 
percent of patients (%), grouped by study cohorts dose group and ADA titer level.  
Plots of drug concentrations will be examined and the influence of ADAs and NAbs on individual 
PK profiles may be evaluated.  Assessment of impact of ADA and NAbs on safety and efficacy 
may be provided.  
11.4.7.  Analysis of Pharmacodynamics Data  
The exploratory biom arker data will be summarized by descriptive statistics.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 61 of 75 
CONFIDENTIAL  11.5. Additional Statistical Data Handling Conventions  
The following analysis and data conventions will be followed:  
Definition of baseline:  
 The baseline assessment will be the latest, valid pre -first-dose assessment available.  
General rules for handling missing data:  
 Rules for handling missing data for assessment (other than efficacy)  
 If the start date of an AE or concomitant medication is incomplete or missing, it will 
be assumed to have occurred on or after the intake of study medication, except if an 
incomplete date (eg, month and year) clearly indicates that the event started prior to 
treatment. If the partial date indicates the same month or year of the intake of study 
medication date, then the start  date by the study medication intake date will be 
imputed; otherwise, the missing day or month by the first day or the first month will 
be imputed.  
 No imputations for missing laboratory data, vital sign data, or physical examination 
data will be made.  
Visit windows:  
 Assessments taken outside of protocol allowable windows will be displayed 
according to the case report form (CRF) assessment recorded by the investigator.  
Unscheduled assessments:  
 Extra assessments (laboratory data or vital signs associated with non -protocol clinical 
visits or obtained in the course of investigating or managing AEs) will be included in 
listings, but not summaries. If more than 1 laboratory value is available for a given 
visit, the first observation will be used in summaries a nd all observations will be 
presented in listings.  
11.6. Statistical Considerations Surrounding the Premature Termination 
of a Study  
If the study is terminated prematurely, only those parameters required for the development 
program and/or reporting to regulatory  authorities will be summarized. Investigator and sponsor 
responsibilities surrounding the premature termination of a study are presented in Section  17.1. 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 62 of 75 
CONFIDENTIAL  12. QUALITY CONTROL AND QUALITY ASSURANCE  
In accordance with ICH E6, the sponsor is responsible for quality assurance to ensure that the 
study is conducted  and the data generated, recorded, and reported in compliance with the protocol, 
GCP, and any appli cable regulatory requirement(s).  The planned quality assurance and quality 
control procedures for the study are described in this section.    
12.1. Data Management and Electronic Systems  
12.1.1.  Data Management  
A data management  plan specifying all relevant aspects of da ta processing for the study (including 
data validation [quality -checking], cleaning, correcting, releasing) will be maintained and stored 
at Regeneron (Sponsor).  
A medical coding plan will specify the processes and the dictionary used for coding. All data 
coding ( eg, AEs, baseline findings, medication, medical history/surgical history) will be done 
using internationally recognized and accepted dictionaries.  
The CRF data for this study will be collected with an electronic data capture (EDC) tool.  
12.1.2.  Electronic Systems  
Electronic systems that may be used to process and/or collect data in this study will include the 
following:  
 IWRS system – study drug supply  
 EDC system – data capture  
 Statistical Analysis System (SAS) – statistical review and analysis  
 Pharmacovigil ance safety database  
13. STUDY MONITORING  
13.1. Monitoring of Study Sites  
The study monitor and/or designee (eg, contract research organization [CRO] monitor) will visit 
each site prior to enrollment of the first patient, and periodically during the study.   
The investigator must allow study -related monitoring.  
The study monitors will perform ongoing source data review to verify that data recorded in the 
CRF by authorized  site personnel are accurate, complete, and verifiable from source documents, 
that the safety and rights of patients are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreements, ICH GCP, 
and all applicable regulatory requirements  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 63 of 75 
CONFIDENTIAL  13.2. Source Document Requirements  
Investigators  are required to prepare and maintain adequate and accurate patient records (source 
documents).  
The investigator must keep all source documents on file with the CRF (throughout this protocol, 
CRF refers  to either a paper CRF or an electronic CRF).  Case report forms and source documents 
must be available at all times for inspection by authorized representatives of the sponsor and 
regulatory authorities.  
13.3. Case Report Form Requirements  
Study data obtained in the course of the clinical study will be rec orded on electronic Case Report 
Forms (CRFs) within the EDC system by trained site personnel. All required CRFs must be 
completed for each and every patient enrolled in the study. After review of the clinical data for 
each patient, the investigator must pr ovide an electronic signature. A copy of each patient  CRF 
casebook is to be retained by the investigator as part of the study record and must be available at 
all times for inspection by authorized representatives of the sponsor and regulatory authorities.  
14. AUDITS AND INSPECTIO NS 
This study may be subject to a quality assurance audit or inspection by the sponsor or regulatory 
authorities.  Should this occur, the investigator is responsible for:  
Informing the sponsor of a planned inspection by the authorities as soon as notification is received, 
and authorizing the sponsor’s participation in the inspection  
Providing access to all necessary  facilities, study data, and documents for the inspection or audit  
Communicating any information  arising from inspection by the regulatory authorities to the 
sponsor immediately  
Taking all appropriate measures  requested by the sponsor to resolve the problems found during 
the audit or inspection  
Documents subject to audit or inspection include but are not limited to all source d ocuments, CRFs, 
medical records, correspondence, ICFs, IRB/EC files, documentation of certification and quality 
control  of supporting laboratories, and records relevant to the study maintained in any supporting 
pharmacy facilities. Conditions of study mate rial storage are also subject to inspection. In addition, 
representatives of the sponsor may observe the conduct of any aspect of the clinical study or its 
supporting activities both within and outside of the investigator's institution.  
In all instances, t he confidentiality of the data must be respected.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 64 of 75 
CONFIDENTIAL  15. ETHICAL AND REGULATO RY CONSIDERATIONS  
15.1. Good Clinical Practice Statement  
It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study 
will be conducted  in accordance  with the ethical principles that have their origin in the Declaration 
of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory 
requirements.  
15.2. Assent and Informed Consent  
The principles of informed consent are described  in ICH guidelines for Good Clinical Practice.  
The ICF used by the investigator must be reviewed and approved by the sponsor prior to 
submission to the appropriate IRB/EC. A copy of the IRB/EC -approved ICF and documentation 
of approval must be provided to  the sponsor before study drug will be shipped to the study site.  
It is the responsibility of the investigator or designee (if acceptable by local regulations) to obtain 
written informed consent from each patient and his/her parent(s) or legal guardian(s) prior to the 
patient’s participation in the study and after the aims, methods, objectives, and potential hazards 
of the study have been explained to the fullest possible extent in language that the patient and the 
parent(s) or legal guardian(s) can underst and. The ICF should be signed and dated by the patient’s 
parent(s) or legal guardian(s) and the same investigator or designee who explained the ICF.  
Local law must be observed in deciding whether 1 or both parents/guardians consent is required.  
If only 1 parent or guardian signs the consent form, the investigator must document the reason the 
other parent or guardian did not sign. The patient may also be required to sign and date the ICF, 
as determined by the IRB/EC and in accordance with the local regulati ons and requirements.  
 Patients who can write but cannot read will have the assent form read to them before 
writing their name on the form.  
 Patients who can understand but who can neither write nor read will have the ICF 
read to them in presence of an impar tial witness, who will sign and date the ICF to 
confirm that informed consent was given.  
The original ICF must be retained by the investigator as part of the patient’s study record, and a 
copy of the signed ICF must be given to the patient’s parent(s) or l egal guardian(s).  
If new safety information results in significant changes in the risk/benefit assessment, the ICF must 
be reviewed and updated appropriately. All study patients and their parent(s) or legal guardian (s) 
must be informed of the new informati on and provide their written consent if they wish the patient 
to continue in the study. The original signed revised ICF must be maintained in the patient’s study 
record and a copy must be given to the patient’s parent(s) or legal guardian(s).  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 65 of 75 
CONFIDENTIAL  15.3. Patients Conf identiality and Data Protection  
The investigator must take all appropriate measures to ensure that the anonymity of each study 
patient will be maintained. Patients should be identified by a patient identification number only, 
on CRFs or other documents sub mitted to the sponsor. Documents that will not be submitted to 
the sponsor (eg, signed ICF) must be kept in strict confidence.  
The patient's and investigator's personal data, which may be included in the sponsor database, will 
be treated in compliance with  all applicable laws and regulations. The sponsor shall take all 
appropriate measures to safeguard and prevent access to this data by any unauthorized third party.  
15.4. Institutional Review Board/Ethics Committee  
An appropriately constituted IRB/EC, as described in ICH guidelines for GCP, must review and 
approve:  
 The protocol, assent, ICF, and any other materials to be provided to the patients (eg, 
advertising) before any patient may be enrolled in the study  
 Any amendment or modification to the study pro tocol, assent or ICF before 
implementation, unless the change is necessary to eliminate an immediate hazard to 
the patient, in which case the IRB/EC should be informed as soon as possible  
 Ongoing studies on an annual basis or at intervals appropriate to t he degree of risk  
In addition, the IRB/EC should be informed of any event likely to affect the safety of patients or 
the continued conduct of the clinical study.  
A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their func tions 
must be received by the sponsor prior to shipment of drug supplies to the investigator. The approval 
letter should include the study number and title, the documents reviewed, and the date of the 
review.  
Records of the IRB/EC review and approval of al l study documents (including approval of ongoing 
studies) must be kept on file by the investigator.  
15.5. Clinical Study Data Transparency  
Final study  results will be published on a public clinical trial website according to applicable local 
guidelines and regul ations.  Treatment codes will be disseminated to each investigation site 
thereafter.  
16. PROTOCOL AMENDMENTS  
The sponsor may not implement a change in the design of the protocol, assent or ICF without an 
IRB/EC -approved amendment . 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 66 of 75 
CONFIDENTIAL  17. PREMATURE TERMINATIO N OF THE STUDY OR 
CLOSE -OUT OF A SITE  
17.1. Premature Termination of the Study  
The sponsor  has the right to terminate the study prematurely.  Reasons may include efficacy, 
safety, or futility, among others. Should the sponsor decide to terminate the study, the 
investigat or(s) will be notified in writing.  
17.2. Close -out of a Site  
The sponsor and the investigator have the right to close -out a site prematurely.  
Investigator’s Decision  
The investigator must notify the sponsor of a desire to close -out a site in writing, providing a t 
least 30 days’ notice. The final decision should be made through mutual agreement with the 
sponsor. Both parties will arrange the close -out procedures after review and consultation.  
Sponsor’s Decision  
The sponsor will notify the investigator(s) of a deci sion to close -out a study site in writing.  
Reasons may include the following, among others:  
 The investigator has received all items and information necessary to perform the 
study, but has not enrolled any patient within a reasonable period of time  
 The in vestigator has violated any fundamental obligation in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or breach of any applicable ICH 
guidelines  
 The total number of patients required for the study are enrolled earlier than expected  
In all cases, the appropriate IRB/EC and Health Authorities must be informed according to 
applicable regulatory requirements, and adequate consideration must be given to th e protection of 
the patients’ interests.  
18. STUDY DOCUMENTATION  
18.1. Certification of Accuracy of Data  
A declaration  assuring the accuracy and content of the data recorded on the CRF/eCRF must be 
signed electronically by the investigator. This signed declaration accompanies each set of patient  
final CRF/eCRF that will be provided to the sponsor.  
18.2. Retention of Records  
The investigator must retain all essential study documents, including ICFs, source documents, 
investigator copies of CRFs, and  drug accountability records for at least 15  years following the 
completion or discontinuation of the study, or longer, if a longer period is required by relevant 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 67 of 75 
CONFIDENTIAL  regulatory authorities. The investigator must obtain written approval from the sponsor before  
discarding or destroying any essential study documents during the retention period following study 
completion or discontinuation. Records must be destroyed in a manner that ensures confidentiality.  
If the investigator's personal situation is such that archiving can no longer be ensured, the 
investigator must inform the sponsor (written notification) and the relevant records will be 
transferred to a mutually agreed -upon destination.  
19. DATA QUALITY ASSU RANCE  
In accordance  with ICH E6, the sponsor is responsible for quality assurance to ensure that the 
study is conducted and the data generated, recorded, and reported in compliance with the protocol, 
GCP, and any applicable regulatory requirement(s).  The planned quality assurance and quality 
control procedures for the study are summarized.  
Data Management  
The sponsor is responsible for the data management of this study including quality checking of the 
data (Section  12.1.1 ). 
Study Monitoring  
The investigator  must allow study -related monitoring, IRB/EC review, audits, and inspections 
from relevant health regulatory authorities, and provide direct acces s to source data documents 
(Section  13.1, Section  13.2, Section  14).   
The study monitors will perform ongoing source data review to verify that data recorded in the 
CRF by authorized site  personnel are accurate, complete, and verifiable from source documents, 
that the safety and rights of patients are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreemen ts, ICH GCP, 
and all applicable regulatory requirements (Section  13.1).   
All patient data collected  during the study will be recorded on paper or electronic CRF unless the 
data are transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator 
is responsible for affirming that data entries in the CRF are accurate and corre ct by electronically 
signing a declaration that accompanies each set of patient final CRF (Section  13.3 and 
Section  18.1).  
Study Documentation  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF (Section  13.2).  
The investigator will retain all records and documents, including signed ICFs, pertaining to the 
conduct of this study for at least 15 years after study completion, unl ess local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the sponsor. No records may be transferred to 
another location or party without writt en notification to the sponsor (Section  18.2).  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 68 of 75 
CONFIDENTIAL  20. CONFIDENTIALITY  
Confidentiality of information is provided as a separate agreement.  
21. FINANCING AND IN SURANCE  
Financing and insurance information is provided as a separate agreement.  
22. PUBLICATION POLICY  
The publication policy is provided as a separate agreement.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 69 of 75 
CONFIDENTIAL  23. REFERENCES  
Anagnostou K, Clark A, King Y, et al. Efficacy and safety of high -dose peanut oral 
immunotherapy with factors predicting outcome. Clin Exp Allergy. 2011 Sep;41(9):1273 -81. 
Anagnostou K, Islam S, King Y. Assessing the efficacy of oral immunotherapy for the 
desensitisation of peanut allergy in children (STOP II): a Phase 2 randomised control led trial 
Lancet 2014; 383 (9925), 1297 -1304.  
Bock SA, Sampson HA, Atkins FM, et al. Double -blind, placebo -controlled food challenge 
(DBPCFC) as an office procedure: a manual.  JACI 1988; 82:986 –97. 
Brody D, Zhanh, X, Kit B, Dillon C. Reference values and factors associated with exhaled nitric 
oxide: U.S. youth and adults. Respiratory Medicine (2013) 107, 1682 -1691.  
Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: Phase 3 Randomized, Double -
Blind, Placebo -Controlled, Parallel -Group Study to Evalu ate Dupilumab Efficacy/Safety in 
Patients with Uncontrolled, Moderate -to-Severe Asthma. Adv Ther. 2018 May 3. doi: 
10.1007/s12325 -018-0702 -4. [Epub ahead of print].  
Dunlop J, Keet C. Epidemiology of Food Allergy. Immunol Allergy Clin North Am. 2018 
Feb;38( 1):13 -25. 
Dyer AA. Epidemiology of Food. Allergy, Asthma Proc, 2015, 36:58 -64. 
Glaumann S, Nilsson C, Asarnoj A, et al. IgG4 antibodies and peanut challenge outcome in 
children IgE -sensitized to peanut. Pediatr Allergy Immunol. 2015 Jun;26(4):386 -9. doi: 
10.1111/pai.12370. Epub 2015 Apr 21  
Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of 
childhood food allergy in the United States. Pediatrics 2011;  128, e9 –e17 
Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ,  Lockey RF, et al. Revised 
nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the 
World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832 -836. 
Jones SM, Pons JL, Roberts AM, et al. Clinical eff icacy and immune regulation with peanut oral 
immunotherapy. J Allergy Clin Immunol 2009; 124:292 -300. 
Menou A, Babeanu H, Paruit H, et al. Normal values of offline exhaled and nasal nitric oxide in 
healthy children and teens using chemiluminescence. J. Bre ath Res. 11 (2017) 036008.  
Muraro A. Roberts G. Clark A. E, et al. The management of anaphylaxis in childhood: position 
paper of the European academy of allergology and clinical immunology. Allergy. 2007;62(8):857 -
871. 
Nwaru BI, Hickstein L, Panesar SS, et  al. EAACI Food Allergy and Guidelines Group. Prevalence 
of common food allergies in Europe: a systemic review and meta -analysis. Allergy, 2014;69;992 -
1007.  
Percival E, Bhatia R, Preece K, et al. Reproducibility of serum IgE, Ara h2 skin prick testing and 
fraction of exhaled nitric oxide for predicting clinical peanut allergy in children. Allergy Asthma 
Clin Immunol. (2016) 12:35.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 70 of 75 
CONFIDENTIAL  Preece K, Bhatia R, Belcher J, et al. The fraction of exhaled nitric oxide improves prediction of 
clinical allergic reaction to peanut challenge in children. Clin Exp Allergy. 2014 Mar;44(3):371 -
80. 
Sampson HA, Muñoz -Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. 
Second symposium on the definition and management of anaphylaxis: summary report --Second 
National Ins titute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium. J Allergy Clin Immunol. 2006; 117(2): 391 -7. 
Sicherer SH, Munoz -Furlong A, Godbold JH, et al. US prevalence of self -reported peanut, tree 
nut, and sesame allergy: 11 y ear follow -up. JACI, 2010, 125:1322 -6. 
Simons FE, Ardusso LR, Bilò MB, Cardona V, Ebisawa M, El -Gamal YM, et al. International 
consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014;30;7(1):9.  
Simons FE. Anaphylaxis pathogenesis and treatment. Allerg y. 2011 Jul;66 Suppl 95:31 -4. doi: 
10.1111/j.1398 -9995.2011.02629  
Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral 
immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin 
Immunol  2011; 127(3):654 -60. 
Vickery BP, Scurlock AM, Kulis M. Sustained unresponsiveness to peanut in subjects who have 
completed peanut oral immunotherapy. JACI 2014; 133 (2), 468 - 475. 
Vickery BP, Vereda A, Casale TB, et al. AR101 Oral Immunotherapy for Peanu t Allergy. N Engl 
J Med. 2018 Nov 22.  doi: 10.1056/NEJMoa1812856. Epub 2018 Nov 18.  
Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled 
persistent asthma despite use of medium -to-high-dose inhaled corticosteroids  plus a long -acting 
β2 agonist: a randomised double -blind placebo -controlled pivotal phase 2b dose -ranging trial. 
Lancet 2016; 388 (10039): 31 -44. 
Wong Y, Hussey -Freeland D, Nadeau K, Food allergy: immune mechanisms, diagnosis and 
immunotherapy. Nat Rev Im mun 2016  
Wood R. Oral Immunotherapy for Food Allergy.  J Investig Allergol Clin Immunol 2017; 27(3) 
1-23. 
Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and 
immunotherapy. Nat Rev Immunol. 2016 Dec;16(12):751 -765. doi: 10.1038/nr i.2016.111. Epub 
2016 Oct 31.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 71 of 75 
CONFIDENTIAL  24. INVESTIGATOR’S AGREE MENT  
I have read the attached protocol: “A Study to Evaluate the Efficacy and Safety of Dupilumab 
Monotherapy in Pediatric Patients with Peanut Allergy” and agree to abide by all provisions set 
forth therei n. 
I agree to comply with the current International Council for Harmonisation Guideline for Good 
Clinical Practice and the laws, rules, regulations, and guidelines of the community, country, state, 
or locality relating to the conduct of the clinical study.  
I also agree that persons debarred from conducting or working on clinical studies by any court or 
regulatory agency will not be allowed to conduct or work on studies for the sponsor or a partnership 
in which the sponsor is involved. I will immediately disclose it in writing to the sponsor if any 
person who is involved in the study is debarred, or if any proceeding for debarment is pending, or, 
to the best of my knowledge, threatened.  
This document contains confidential information of the sponsor, which must not be disclosed to 
anyone other than the recipient study staff and members of the IRB/EC. I agree to ensure that this 
information will not be used for any purpose other than the evaluation or conduct of the clinical 
investigation without the prior wr itten consent of the sponsor.  
 
 
 
   
(Signature of Investigator)   (Date)  
   
(Printed Name)    
 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 72 of 75 
CONFIDENTIAL  APPENDIX  1. PEANUT DBPCFC SCHEDU LE OF DOSING 
PERFORMED AT SCREENI NG AND WEEKS 24 AND 36 
 Challenge Doses 
  
Amount of Peanut 
Protein at Each 
Challenge Dose (mg)  
Amount of Peanut 
Flour with 50% 
Protein Content (mg) Cumulative 
Amount of 
Peanut Protein 
(mg) at Screening Cumulative Amount 
of Peanut Protein 
(mg) on Study 
(Weeks 24 and 36)  
Screening 1 2 1 1 
Screening  3 6 4 4 
Screening  10 20 14 14 
Screening  30 60 44 44 
Screening  100 200 144 144 
Endpoint  300 600 - 444 
Endpoint  600 1200  - 1044 
Endpoint  1000  2000   2044  
Note: The DBPCFC is to be conducted as 2 challenges, each on a separate day using a placebo (artificially peanut -flavored oat 
protein) for one challenge and peanut (as defatted peanut protein) for the other. The oral food challenge is to be performed under 
double -blind conditions so that neither the patient, nor the patient’s caregiver, nor any of the clinic staff (save for the unblinde d 
preparer of the ch allenge foods) knows which challenge contains the peanut or the placebo. The clinic staff may not be unblinded 
as to the order of the 2 parts (peanut and placebo) of the DBPCFC until after completion of the observation period of the sec ond 
part of the chal lenge for the scre ening challenge only.  For weeks 24 and 36, the study team will remain blinded to the order of 
the exposure for each challenge date.  
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 73 of 75 
CONFIDENTIAL  APPENDIX  2. ALLERGY REACTION SEV ERITY GRADING  
The Consortium of Food Allergy Research (CoFAR) grading system for alle rgic reactions  
 
 
PRACTALL consensus report on DBPCFC, and with the CoFAR grading system for allergic 
reactions, are provided as a general guide.  
Mild Symptoms :  
• Skin – limited (few) or localized hives, swelling (eg, mild lip edema), skin flushing (eg, few areas of faint erythema) or 
pruritus (mild, eg, causing occasional scratching)  
• Respiratory – rhinorrhea (eg, occasional sniffling or sneezing), nasal con gestion, occasional cough, throat discomfort  
• Gastrointestinal (GI) – mild abdominal discomfort (including mild nausea), minor vomiting (typically a single episode) 
and/or a single episode of diarrhea  
Moderate Symptoms:  
• Skin – systemic hives (eg, numerous or widespread hives), swelling (eg, significant lip or face edema), pruritus 
causing protracted scratching, more than a few areas of erythema or pronounced erythema  
• Respiratory – throat tightness without hoarseness, persistent cough, wheezing without dyspnea  
• GI – persistent moderate abdominal pain/cramping/nausea, more than a single episode of vomiting and/or diarrhea 
Severe Symptoms:  
• Skin – severe generalized urticaria/angioedema/erythema  
• Respiratory – laryngeal edema, throat tightness with hoarseness, wheezing with dyspnea, stridor  
• GI – severe abdominal pain/cramping/repetitive vomiting and/or diarrhea  
• Neurological – change in mental status  
• Circulatory – clinically significant hypotension  
   
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 74 of 75 
CONFIDENTIAL  APPENDIX  3. CRITERIA FOR SUSPECT ED DIAGNOSIS AND 
SEVERITY GRADING OF ANAPHYLAXIS  
Anaphylaxis is likely when any 1 of the 3 following sets of criteria is fulfilled:  
1.  Acute onset of an illness (minutes to hours) with involvement of:  
 Skin/mucosal tissu e (eg, generalized hives, itch or flush, swollen lips/tongue/uvula) 
AND  
 Airway compromise (eg, dyspnea, stridor, wheeze/ bronchospasm, hypoxia, reduced 
PEF) AND/OR  
 Reduced BP or associated symptoms (eg, hypotonia, syncope, incontinence)  
2. Two or more of the following that occur rapidly after exposure to the allergen (minutes to 
hours):  
 Skin/mucosal tissue (eg, generalized hives, itch/flush, swollen lips/tongue/uvula)  
 Airway compromise (eg, dyspnea, stridor wheeze/bronchospasm, hypoxia, reduced 
PEF)  
 Reduced BP  or associated symptoms (eg, hypotonia, syncope, incontinence)  
 Persistent GI symptoms (eg, nausea, vomiting, crampy abdominal pain)  
3. Reduced BP after exposure to the allergen (minutes to hours):  
 Infants and Children: low systolic BP (age -specific) or >30% d rop in systolic BP*  
 Adults: systolic BP <90 mm Hg or >30% drop from their baseline  
* Low systolic BP for children is defined as <70 mm Hg from 1 month to 1 year; less than (70 mm 
Hg + [2 x age]) from 1 to 10 years; and <90 mm Hg from age 11 to 17 years.  
Note: Isolated skin or mucosal lesions following the ingestion of a food constitute a “food -induced 
allergic reaction”.  
Criteria for Severity Grading (Muraro 2007)  
Staging System of Severity of Anaphylaxis 
Stage Defined By 
1. Mild (skin  & subcutaneous tissues, GI, 
&/or mild respiratory) Flushing, urticaria,  periorbital or facial  angioedema; mild 
dyspnea, wheeze or upper respiratory symptoms; mild 
abdominal pain and/or emesis 
2. Moderate (mild  symptoms + 
features suggesting moderate 
respiratory, cardiovascular or GI 
symptoms) Marked dysphagia, hoarseness and/or stridor; shortness 
of breath, wheezing & retract ions; crampy abdominal 
pain, recurrent vomiting and/or diarrhea; and/or mild 
dizziness 
3. Severe  (hypox ia, hypotension, or 
neurological compromise) Cyanosis or SpO2 ≤92% at any stage, hypotension, 
confusion, collapse, loss of consciousness; or 
incontinence 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Clinical Study Protocol  R668 -ALG -1702 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc .  Page 75 of 75 
CONFIDENTIAL  SIGNATURE OF SPONSOR ’S RESPONSIBLE OFFIC ERS  
(Medical/Study Director, Regulatory Representative, Clinical Study Team Lead, and 
Biostatistician)  
To the  best of my knowledge, this report accurately describes the conduct of the study.  
Study Title:  A Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in 
Pediatric Patients with Peanut Allergy  
Protocol Number : R668 -ALG -1702  
Protocol Version :  R668 -ALG -1702 Amendment 2 
 
 
See appended electronic signature page  
Sponsor’s Responsible Medical/Study Director  
 
 
See appended electronic signature page  
Sponsor’s Responsible Regulatory Liaison  
 
 
See appended electronic signature page  
Sponsor’s Responsible  Clinical Study Team Lead  
 
 
See appended electronic signature page  
Sponsor’s Responsible Biostatistician  
 
 
 
                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
Signature Page for VV-RIM-00101740 v1.0
Signature Page for VV-RIM-00101740 v1.0 ApprovedESig Approval
-2020 12:47:22 GMT+0000
ESig Approval
20 12:55:10 GMT+0000
ESig Approval
-2020 14:26:28 GMT+0000
ESig Approval
000                                        VV-RIM-00101740-1.0 Approved - 30 Mar 2020 GMT-5:00
